(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 418 014 A1**

EUROPEAN PATENT APPLICATION

(21) Application number: 90309875.4

(22) Date of filing: 10.09.90

(51) Int. Cl.5: **C12N 15/12**, C12P 21/02, A61K 37/02, C12P 21/08, G01N 33/68

(30) Priority: 11.09.89 US 405370
13.10.89 US 421417
10.05.90 US 523635

(43) Date of publication of application:
20.03.91 Bulletin 91/12

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **IMMUNEX CORPORATION**
51 University Street
Seattle Washington 98101(US)

(72) Inventor: **Smith, Craig A.**
20405 5th West
Seattle, Washington 98119(US)
Inventor: **Goodwin, Raymond G.**
3322 8th Avenue West
Seattle, Washington 98119(US)
Inventor: **Beckmann, Patricia M.**
15875 Nesika Bay Road
Poulsbo, Washington 98370(US)

(74) Representative: **Bannerman, David Gardner**
Withers & Rogers 4 Dyer's Buildings Holborn
London, EC1N 2JT(GB)

(54) Tumor necrosis factor-alpha and -beta receptors.

(57) Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.

EP 0 418 014 A1

TUMOR NECROSIS FACTOR-α AND -β RECEPTORS

BACKGROUND OF THE INVENTION

The present invention relates generally to cytokine receptors and more specifically to tumor necrosis factor receptors.

Tumor necrosis factor-α (TNFα, also known as cachectin) and tumor necrosis factor-β (TNFβ, also known as lymphotoxin) are homologous mammalian endogenous secretory proteins capable of inducing a wide variety of effects on a large number of cell types. The great similarities in the structural and functional characteristics of these two cytokines have resulted in their collective description as "TNF." Complementary cDNA clones encoding TNFα (Pennica et al., *Nature 312*:724, 1984) and TNFβ (Gray et al., *Nature 312*:721, 1984) have been isolated, permitting further structural and biological characterization of TNF.

TNF proteins initiate their biological effect on cells by binding to specific TNF receptor (TNF-R) proteins expressed on the plasma membrane of a TNF-responsive cell. TNFα and TNFβ were first shown to bind to a common receptor on the human cervical carcinoma cell line ME-180 (Aggarwal et al., *Nature 318*:665,1985). Estimates of the size of the TNF-R determined by affinity labeling studies ranged from 54 to 175 kDa (Creasey et al, *Proc. Natl. Acad. Sci. USA 84*:3293, 1987; Stauber et al., *J. Biol. Chem. 263*:19098, 1988; Hohmann et al., *J. Biol. Chem. 264*:14927, 1989). Although the relationship between these TNF-Rs of different molecular mass is unclear, Hohmann et al. (*J. Biol. Chem. 264*:14927, 1989) reported that at least two different cell surface receptors for TNF exist on different cells kDa, respectively. None of the above publications, however, reported the purification to homogeneity of cell surface TNF receptors.

In addition to cell surface receptors for TNF, soluble proteins from human urine capable of binding TNF have also been identified (Peetre et al., *Eur. J. Haematol. 41*:414, 1988; Seckinger et al., *J. Exp. Med. 167*:1511, 1988; Seckinger et al., *J. Biol. Chem. 264*:11966, 1989; UK Patent Application, Publ. No. 2 218 101 A to Seckinger et al.; Engelmann et al., *J. Biol. Chem. 264*:11974, 1989). The soluble urinary TNF binding protein disclosed by UK 2 218 101 A has a partial N-terminal amino acid sequence of Asp-Ser-Val-Cys-Pro-, which corresponds to the partial sequence disclosed later by Engelmann et al. (1989). The relationship of the above soluble urinary binding proteins was further elucidated after original parent application (U.S. Serial No. 403,241) of the present application was filed, when Engelmann et al. reported the identification and purification of a second distinct soluble urinary TNF binding protein having an N-terminal amino acid sequence of Val-Ala-Phe-Thr-Pro- (*J. Biol. Chem. 265*:1531, 1990). The two urinary proteins disclosed by the UK 2 218 101 A and the Engelmann et al. publications were shown to be immunochemically related to two apparently distinct cell surface proteins by the ability of antiserum against the binding proteins to inhibit TNF binding to certain cells.

More recently, two separate groups reported the molecular cloning and expression of a human 55 kDa TNF-R (Loetscher et al., *Cell 61*:351, 1990; Schall et al., *Cell 61*:361, 1990). The TNF-R of both groups has an N-terminal amino acid sequence which corresponds to the partial amino acid sequence of the urinary binding protein disclosed by UK 2 218 101 A, Engelmann et al. (1989) and Englelmann et al. (1990).

In order to elucidate the relationship of the multiple forms of TNF-R and soluble urinary TNF binding proteins, or to study the structural and biological characteristics of TNF-Rs and the role played by TNF-Rs in the responses of various cell populations to TNF or other cytokine stimulation, or to use TNF-Rs effectively in therapy, diagnosis, or assay, purified compositions of TNF-R are needed. Such compositions, however, are obtainable in practical yields only by cloning and expressing genes encoding the receptors using recombinant DNA technology. Efforst to purify the TNF-R molecule for use in biochemical analysis or to clone and express mammalian genes encoding TNF-R, however, have been impeded by lack of a suitable source of receptor protein or mRNA. Prior to the present invention, no cell lines were known to express high levels of TNF-R constitutively and continuously, which precluded purification of receptor for sequencing or construction of genetic libraries for cDNA cloning.

SUMMARY OF THE INVENTION

The present invention provides isolated TNF receptors and DNA sequences encoding mammalian tumor necrosis factor receptors (TNF-R), in particular, human TNF-Rs. Such DNA sequences include (a)

cDNA clones having a nucleotide sequence derived from the coding region of a native TNF-R gene; (b) DNA sequences which are capable of hybridization to the cDNA clones of (a) under moderately stringent conditions and which encode biologically active TNF-R molecules; or (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R molecules. In particular, the present invention provides DNA sequences which encode soluble TNF receptors.

The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, recombinant TNF-R molecules produced using the recombinant expression vectors, and processes for producing the recombinant TNF-R molecules using the expression vectors.

The present invention also provides isolated or purified protein compositions comprising TNF-R, and, in particular, soluble forms of TNF-R.

The present invention also provides compositions for use in therapy, diagnosis, assay of TNF-R, or in raising antibodies to TNF-R, comprising effective quantities of soluble native or recombinant receptor proteins prepared according to the foregoing processes.

Because of the ability of TNF to specifically bind TNF receptors (TNF-Rs), purified TNF-R compositions will be useful in diagnostic assays for TNF, as well as in raising antibodies to TNF receptor for use in diagnosis and therapy. In addition, purified TNF receptor compositions may be used directly in therapy to bind or scavenge TNF, thereby providing a means for regulating the immune activities of this cytokine.

These and other aspects of the present invention will become evident upon reference to the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the coding region of various cDNAs encoding human and murine TNF-Rs. The leader sequence is hatched and the transmembrane region is solid.

Figure 2A-2B depict the partial cDNA sequence and derived amino acid sequence of the human TNF-R clone 1. Nucleotides are numbered from the beginning of the 5′ untranslated region. Amino acids are numbered from the beginning of the signal peptide sequence. The putative signal peptide sequence is represented by the amino acids -22 to -1. The N-terminal leucine of the mature TNF-R protein is underlined at position 1. The predicted transmembrane region from amino acids 236 to 265 is also underlined. The C-termini of various soluble TNF-Rs are marked with an arrow (↕).

Figure 3A-3C depict the cDNA sequence and derived amino acid sequence of murine TNF-R clone 11. The putative signal peptide sequence is represented by amino acids -22 to -1. 1. The N-terminal valine of the mature TNF-R protein is underlined at position 1. The predicted transmembrane region from amino acids 234 to 265 is also underlined.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein, the terms "TNF receptor" and "TNF-R" refer to proteins having amino acid sequences which are substantially similar to the native mammalian TNF receptor amino acid sequences, and which are biologically active, as defined below, in that they are capable of binding TNF molecules or transducing a biological signal initiated by a TNF molecule binding to a cell, or cross-reacting with anti-TNF-R antibodies raised against TNF-R from natural (i.e., nonrecombinant) sources. The mature full-length human TNF-R is a glycoprotein having a molecular weight of about 80 kilodaltons (kDa). As used throughout the specification, the term "mature" means a protein expressed in a form lacking a leader sequence as may be present in full-length transcripts of a native gene. Experiments using COS cells transfected with a cDNA encoding full-length human TNF-R showed that TNF-R bound ^{125}I-TNFα with an apparent K_a of about 5×10^9 M^{-1}, and that TNF-R bound ^{125}I-TNFβ with an apparent K_a of about 2×10^9 M^{-1}. The terms "TNF receptor" or "TNF-R" include, but are not limited to, analogs or subunits of native proteins having at least 20 amino acids and which exhibit at least some biological activity in common with TNF-R, for example, soluble TNF-R constructs which are devoid of a transmembrane region (and are secreted from the cell) but retain the ability to bind TNF. Various bioequivalent protein and amino acid analogs are described in detail below.

The nomenclature for TNF-R analogs as used herein follows the convention of naming the protein (e.g., TNF-R) preceded by either hu (for human) or mu (for murine) and followed by a Δ (to designate a deletion) and the number of the C-terminal amino acid. For example, huTNF-RΔ235 refers to human TNF-R having Asp^{235} as the C-terminal amino acid (i.e., a polypeptide having the sequence of amino acids 1-235 of Figure 2A). In the absence of any human or murine species designation, TNF-R refers generically to mammalian TNF-R. Similarly, in the absence of any specific designation for deletion mutants, the term TNF-R means all forms of TNF-R, including mutants and analogs which possess TNF-R biological activity.

"Soluble TNF-R" or "sTNF-R" as used in the context of the present invention refer to proteins, or substantially equivalent analogs, having an amino acid sequence corresponding to all or part of the extracellular region of a native TNF-R, for example, huTNF-RΔ235, huTNF-RΔ185 and huTNF-RΔ163, or amino acid sequences substantially similar to the sequences of amino acids 1-163, amino acids 1-185, or amino acids 1-235 of Figure 2A, and which are biologically active in that they bind to TNF ligand. Equivalent soluble TNF-Rs include polypeptides which vary from these sequences by one or more substitutions, deletions, or additions, and which retain the ability to bind TNF or inhibit TNF signal transduction activity via cell surface bound TNF receptor proteins, for example huTNF-RΔx, wherein x is selected from the group consisting of any one of amino acids 163-235 of Figure 2A. Analogous deletions may be made to muTNF-R. Inhibition of TNF signal transduction activity can be determined by transfecting cells with recombinant TNF-R DNAs to obtain recombinant receptor expression. The cells are then contacted with TNF and the resulting metabolic effects examined. If an effect results which is attributable to the action of the ligand, then the recombinant receptor has signal transduction activity. Exemplary procedures for determining whether a polypeptide has signal transduction activity are disclosed by Idzerda et al., *J. Exp. Med. 171*:861 (1990); Curtis et al., *Proc. Natl. Acad. Sci. USA 86*:3045 (1989); Prywes et al., *EMBO J. 5*:2179(1986) and Chou et al., *J. Biol. Chem. 262*:1842 (1987). Alternatively, primary cells or cell lines which express an endogenous TNF receptor and have a detectable biological response to TNF could also be utilized.

The term "isolated" or "purified", as used in the context of this specification to define the purity of TNF-R protein or protein compositions, means that the protein or protein composition is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes. Such compositions, however, can contain other proteins added as stabilizers, carriers, excipients or co-therapeutics. TNF-R is isolated if it is detectable as a single protein band in a polyacrylamide gel by silver staining.

The term "substantially similar," when used to define either amino acid or nucleic acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity of the TNF-R protein as may be determined, for example, in one of the TNF-R binding assays set forth in Example 1 below. Alternatively, nucleic acid subunits and analogs are "substantially similar" to the specific DNA sequences disclosed herein if: (a) the DNA sequence is derived from the coding region of a native mammalian TNF-R gene; (b) the DNA sequence is capable of hybridization to DNA sequences of (a) under moderately stringent conditions (50° C, 2x SSC) and which encode biologically active TNF-R molecules; or DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b) and which encode biologically active TNF-R molecules.

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycan. Protein expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells.

"Biologically active," as used throughout the specification as a characteristic of TNF receptors, means that a particular molecule shares sufficient amino acid sequence similarity with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of TNF, transmitting a TNF stimulus to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti-TNF-R antibodies raised against TNF-R from natural (i.e., nonrecombinant) sources. Preferably, biologically active TNF receptors within the scope of the present invention are capable of binding greater than 0.1 nmoles TNF per nmole receptor, and most preferably, greater than 0.5 nmole TNF per nmole receptor in standard binding assays (see below).

"Isolated DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration

enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used as a source of coding sequences. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

"Nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. DNA sequences encoding the proteins provided by this invention can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.

Isolation of cDNAs Encoding TNF-R

The coding sequence of TNF-R is obtained by isolating a complementary DNA (cDNA) sequence encoding TNF-R from a recombinant cDNA or genomic DNA library. A cDNA library is preferably constructed by obtaining polyadenylated mRNA from a particular cell line which expresses a mammalian TNF-R, for example, the human fibroblast cell line WI-26 VA4 (ATCC CCL 95.1) and using the mRNA as a template for synthesizing double stranded cDNA. The double stranded cDNA is then packaged into a recombinant vector, which is introduced into an appropriate *E. coli* strain and propagated. Murine or other mammalian cell lines which express TNF-R may also be used. TNF-R sequences contained in the cDNA library can be readily identified by screening the library with an appropriate nucleic acid probe which is capable of hybridizing with TNF-R cDNA. Alternatively, DNAs encoding TNF-R proteins can be assembled by ligation of synthetic oligonucleotide subunits corresponding to all or part of the sequence of Figures 2A-2B or 3A-3C to provide a complete coding sequence.

The human TNF receptor cDNAs of the present invention were isolated by the method of direct expression cloning. A cDNA library was constructed by first isolating cytoplasmic mRNA from the human fibroblast cell line WI-26 VA4. Polyadenylated RNA was isolated and used to prepare double-stranded cDNA. Purified cDNA fragments were then ligated into pCAV/NOT vector DNA which uses regulatory sequences derived from pDC201 (a derivative of pMLSV, previously described by Cosman et al., *Nature 312*:768, 1984), SV40 and cytomegalovirus DNA, described in detail below in Example 2. pCAV/NOT has been deposited with the American Type Culture Collection under accession No. ATCC 68014. The pCAV/NOT vectors containing the WI26-VA4 cDNA fragments were transformed into *E. coli* strain DH5α. Transformants were plated to provide approximately 800 colonies per plate. The resulting colonies were harvested and each pool used to prepare plasmid DNA for transfection into COS-7 cells essentially as described by Cosman et al. (*Nature 312*:768, 1984) and Luthman et al. (*Nucl. Acid Res. 11*:1295, 1983). Transformants expressing biologically active cell surface TNF receptors were identified by screening for their ability to bind ^{125}I-TNF. In this screening approach, transfected COS-7 cells were incubated with medium containing ^{125}I-TNF, the cells washed to remove unbound labeled TNF, and the cell monolayers contacted with X-ray film to detect concentrations of TNF binding, as disclosed by Sims et al. *Science 241*:585 (1988). Transfectants detected in this manner appear as dark foci against a relatively light background.

Using this approach, approximately 240,000 cDNAs were screened in pools of approximately 800 cDNAs until assay of one transfectant pool indicated positive foci for TNF binding. A frozen stock of bacteria from this positive pool was grown in culture and plated to provide individual colonies, which were screened until a single clone (clone 11) was identified which was capable of directing synthesis of a surface protein with detectable TNF binding activity. The sequence of cDNA clone 11 isolated by the above method is depicted in Figures 3A-3C.

Additional cDNA clones can be isolated from cDNA libraries of other mammalian species by cross-species hybridization. For use in hybridization, DNA encoding TNF-R may be covalently labeled with a detectable substance such as a fluorescent group, a radioactive atom or a chemiluminescent group by methods well known to those skilled in the art. Such probes could also be used for *in vitro* diagnosis of particular conditions.

Like most mammalian genes, mammalian TNF receptors are presumably encoded by multi-exon genes. Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein, are considered to be within the scope of the present invention.

Other mammalian TNF-R cDNAs are isolated by using an appropriate human TNF-R DNA sequence as a probe for screening a particular mammalian cDNA library by cross-species hybridization.

Proteins and Analogs

The present invention provides isolated recombinant mammalian TNF-R polypeptides. Isolated TNF-R polypeptides of this invention are substantially free of other contaminating materials of natural or endogenous origin and contain less than about 1% by mass of protein contaminants residual of production processes. The native human TNF-R molecules are recovered from cell lysates as glycoproteins having an apparent molecular weight by SDS-PAGE of about 80 kilodaltons (kDa). The TNF-R polypeptides of this invention are optionally without associated native-pattern glycosylation.

Mammalian TNF-R of the present invention includes, by way of example, primate, human, marine, canine, feline, bovine, ovine, equine and porcine TNF-R. Mammalian TNF-Rs can be obtained by cross species hybridization, using a single stranded cDNA derived from the human TNF-R DNA sequence as a hybridization probe to isolate TNF-R cDNAs from mammalian cDNA libraries.

Derivatives of TNF-R within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and carboxyl groups, for example, a TNF-R protein may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.

The primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to TNF-R amino acid side chains or at the N-or C-termini. Other derivatives of TNF-R within the scope of this invention include covalent or aggregative conjugates of TNF-R or its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated peptide may be a a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co-translationally or post-translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the yeast α-factor leader). TNF-R protein fusions can comprise peptides added to facilitate purification or identification of TNF-R (e.g., poly-His). The amino acid sequence of TNF receptor can also be linked to the peptide Asp-Tyr-Lys-Asp- Asp-Asp-Asp-Lys (DYKDDDDK) (Hopp et al., *Bio/Technology* 6:1204,1988.) The latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*.

TNF-R derivatives may also be used as immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures of TNF or other binding ligands. TNF-R derivatives may also be obtained by cross-linking agents, such as M-maleimidobenzoyl succinimide ester and N-hydroxysuccinimide, at cysteine and lysine residues. TNF-R proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromide-activated, bisoxirane-activated, carbonyldiimidazole-activated or tosyl-activated agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking). Once bound to a substrate, TNF-R may be used to selectively bind (for purposes of assay or purification) anti-TNF-R antibodies or TNF.

The present invention also includes TNF-R with or without associated native-pattern glycosylation. TNF-R expressed in yeast or mammalian expression systems, e.g., COS-7 cells, may be similar or slightly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system. Expression of TNF-R DNAs in bacteria such as *E. coli* provides non-glycosylated molecules. Functional mutant analogs of mammalian TNF-R having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A_1-Z, where A_1 is any amino acid except Pro, and Z is Ser or Thr. In this sequence, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A_1 and Z, or an amino acid other than Asn between Asn and A_1.

TNF-R derivatives may also be obtained by mutations of TNF-R or its subunits. A TNF-R mutant, as referred to herein, is a polypeptide homologous to TNF-R but which has an amino acid sequence different

from native TNF-R because of a deletion, insertion or substitution.

Bioequivalent analogs of TNF-R proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues can be deleted (e.g., Cys^{173}) or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. Generally, substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physiochemical characteristics resembling those of the residue to be replaced. Similarly, when a deletion or insertion strategy is adopted, the potential effect of the deletion or insertion on biological activity should be considered. Substantially similar polypeptide sequences, as defined above, generally comprise a like number of amino acids sequences, although C-terminal truncations for the purpose of constructing soluble TNF-Rs will contain fewer amino acid sequences. In order to preserve the biological activity of TNF-Rs, deletions and substitutions will preferably result in homologous or conservatively substituted sequences, meaning that a given residue is replaced by a biologically similar residue. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known. Moreover, particular amino acid differences between human, murine and other mammalian TNF-Rs is suggestive of additional conservative substitutions that may be made without altering the essential biological characteristics of TNF-R.

Subunits of TNF-R may be constructed by deleting terminal or internal residues or sequences. Particularly preferred sequences include those in which the transmembrane region and intracellular domain of TNF-R are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium. The resulting protein is referred to as a soluble TNF-R molecule which retains its ability to bind TNF. A particularly preferred soluble TNF-R construct is TNF-RΔ235 (the sequence of amino acids 1-235 of Figure 2A), which comprises the entire extracellular region of TNF-R, terminating with Asp^{235} immediately adjacent the transmembrane region. Additional amino acids may be deleted from the transmembrane region while retaining TNF binding activity. For example, huTNF-RΔ183 which comprises the sequence of amino acids 1-183 of Figure 2A, and TNF-RΔ163 which comprises the sequence of amino acids 1-163 of Figure 2A, retain the ability to bind TNF ligand as determined using the binding assays described below in Example 1. TNF-RΔ142, however, does not retain the ability to bind TNF ligand. This suggests that one or both of Cys^{157} and Cys^{163} is required for formation of an intramolecular disulfide bridge for the proper folding of TNF-R. Cys^{178}, which was deleted without any apparent adverse effect on the ability of the soluble TNF-R to bind TNF, does not appear to be essential for proper folding of TNF-R. Thus, any deletion C-terminal to Cys^{163} would be expected to result in a biologically active soluble TNF-R. The present invention contemplates such soluble TNF-R constructs corresponding to all or part of the extracellular region of TNF-R terminating with any amino acid after Cys^{163}. Other C-terminal deletions, such as TNF-FΔ157, may be made as a matter of convenience by cutting TNF-R cDNA with appropriate restriction enzymes and, if necessary, reconstructing specific sequences with synthetic oligonucleotide linkers. The resulting soluble TNF-R constructs are then inserted and expressed in appropriate expression vectors and assayed for the ability to bind TNF, as described in Example 1. Biologically active soluble TNF-Rs resulting from such constructions are also contemplated to be within the scope of the present invention.

Mutations in nucleotide sequences constructed for expression of analog TNF-R must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins which would adversely affect translation of the receptor mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed TNF-R mutants screened for the desired activity.

Not all mutations in the nucleotide sequence which encodes TNF-R will be expressed in the final product, for example, nucleotide substitutions may be made to enhance expression, primarily to avoid secondary structure loops in the transcribed mRNA (see EPA 75,444A, incorporated herein by reference), or to provide codons that are more readily translated by the selected host, e.g., the well-known *E. coli* preference codons for *E. coli* expression.

Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion.

substitution; or deletion.

Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462 disclose suitable techniques, and are incorporated by reference herein.

Both monovalent forms and polyvalent forms of TNF-R are useful in the compositions and methods of this invention. Polyvalent forms possess multiple TNF-R binding sites for TNF ligand. For example, a bivalent soluble TNF-R may consist of two tandem repeats of amino acids 1-235 of Figure 2A, separated by a linker region. Alternate polyvalent forms may also be constructed, for example, by chemically coupling TNF-R to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, polyethylene glycol or dextran using conventional coupling techniques. Alternatively, TNF-R may be chemically coupled to biotin, the biotin-TNF-R conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/TNF-R molecules. TNF-R may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti-TNP-IgM, to form decameric conjugates with a valency of 10 for TNF-R binding sites.

A recombinant chimeric antibody molecule may also be produced having TNF-R sequences substituted for the variable domains of either or both of the immunoglubulin molecule heavy and light chains and having unmodified constant region domains. For example, chimeric TNF-R/IgG$_1$ may be produced from two chimeric genes -- a TNF-R/human κ light chain chimera (TNF-R/C$_\kappa$) and a TNF-R/human γ_1 heavy chain chimera (TNF-R/C$_{\gamma 1}$). Following transcription and translation of the two chimeric genes, the gene products assemble into a single chimeric antibody molecule having TNF-R displayed bivalently. Such polyvalent forms of TNF-R may have enhanced binding affinity for TNF ligand. Additional details relating to the construction of such chimeric antibody molecules are disclosed in WO 89/09622 and EP 315062.

Expression of Recombinant TNF-R

The present invention provides recombinant expression vectors to amplify or express DNA encoding TNF-R. Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding mammalian TNF-R or bioequivalent analogs operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below. Such regulatory elements may include an operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.

DNA sequences encoding mammalian TNF receptors which are to be expressed in a microorganism will preferably contain no introns that could prematurely terminate transcription of DNA into mRNA; however, premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C-terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Other embodiments include sequences capable of hybridizing to the sequences of the provided cDNA under moderately stringent conditions (50° C, 2x SSC) and other sequences hybridizing or degenerate to those which encode

biologically active TNF receptor polypeptides.

Recombinant TNF-R DNA is expressed or amplified in a recombinant expression system comprising a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as *E. coli* or yeast such as *S. cerevisiae*, which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed.

Transformed host cells are cells which have been transformed or transfected with TNF-R vectors constructed using recombinant DNA techniques. Transformed host cells ordinarily express TNF-R, but host cells transformed for purposes of cloning or amplifying TNF-R DNA do not need to express TNF-R. Expressed TNF-R will be deposited in the cell membrane or secreted into the culture supernatant, depending on the TNF-R DNA selected. Suitable host cells for expression of mammalian TNF-R include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example *E. coli* or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also be employed to produce mammalian TNF-R using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (*Cloning Vectors: A Laboratory Manual*, Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference.

Prokaryotic expression hosts may be used for expression of TNF-R that do not require extensive proteolytic and disulfide processing. Prokaryotic expression vectors generally comprise one or more phenotypic selectable markers, for example a gene encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli, Bacillus subtilis, Salmonella typhimurium*, and various species within the genera *Pseudomonas, Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species (Bolivar et al., *Gene* 2:95, 1977). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.

Promoters commonly used in recombinant microbial expression vectors include the β-lactamase (penicillinase) and lactose promoter system (Chang et al., *Nature 275*:615, 1978; and Goeddel et al., *Nature 281*:544, 1979), the tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res. 8*:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful bacterial expression system employs the phage λ P_L promoter and cI857ts thermolabile repressor. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2, resident in *E. coli* strain JMB9 (ATCC 37092) and pPLc28, resident in *E. coli* RR1 (ATCC 53082).

Recombinant TNF-R proteins may also be expressed in yeast hosts, preferably from the *Saccharomyces* species, such as *S. cerevisiae*. Yeast of other genera, such as *Pichia* or *Kluyveromyces* may also be employed. Yeast vectors will generally contain an origin of replication from the 2μ yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding TNF-R, sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and *E. coli*, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 or URA3 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the TRP1 or URA3 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan or uracil.

Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem. 255*:2073, 1980) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg. 7*:149, 1968; and Holland et al., *Biochem. 17*:4900, 1978), such as

enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EPA 73,657.

Preferred yeast vectors can be assembled using DNA sequences from pUC18 for selection and replication in *E. coli* (Amp^r gene and origin of replication) and yeast DNA sequences including a glucose-reoressible ADH2 promoter and α-factor secretion leader. The ADH2 promoter has been described by Russell et al. (*J. Biol. Chem. 258*:2674, 1982) and Beier et al. (*Nature 300*:724, 1982). The yeast α-factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. *See, e.g.*, Kurjan et al., *Cell 30*:933, 1982; and Bitter et al., *Proc. Natl. Acad. Sci. USA 81*:5330, 1984. The leader sequence may be modified to contain, near its 3′ end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.

Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA 75*:1929, 1978, selecting for Trp$^+$ transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 µg/ml adenine and 20 µg/ml uracil or URA+ tranformants in medium consisting of 0.67% YNB, with amino acids and bases as described by Sherman et al., *Laboratory Course Manual for Methods in Yeast Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986.

Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% or 4% glucose supplemented with 80 µg/ml adenine and 80 µg/ml uracil. Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4° C prior to further purification.

Various mammalian or insect cell culture systems are also advantageously employed to express recombinant protein. Expression of recombinant proteins in mammalian cells is particularly preferred because such proteins are generally correctly folded, appropriately modified and completely functional. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (*Cell 23*:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5′ or 3′ flanking nontranscribed sequences, and 5′ or 3′ nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology 6*:47 (1988).

The transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources. For example, commonly used promoters and enhancers are derived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence. The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature 273*:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the *Hind* 3 site toward the *Bgh* site located in the viral origin of replication is included. Further, mammalian genomic TNF-R promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Additional details regarding the use of a mammalian high expression vector to produce a recombinant mammalian TNF receptor are provided in Examples 2 and 7 below. Exemplary vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol. 3*:280, 1983).

A useful system for stable high level expression of mammalian receptor cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (*Mol. Immunol. 23*:935, 1986).

In preferred aspects of the present invention, recombinant expression vectors comprising TNF-R cDNAs are stably integrated into a host cell's DNA. Elevated levels of expression product is achieved by selecting for cell lines having amplified numbers of vector DNA. Cell lines having amplified numbers of vector DNA are selected, for example, by transforming a host cell with a vector comprising a DNA sequence which encodes an enzyme which is inhibited by a known drug. The vector may also comprise a DNA sequence which encodes a desired protein. Alternatively, the host cell may be co-transformed with a second vector which comprises the DNA sequence which encodes the desired protein. The transformed or co-transformed

host cells are then cultured in increasing concentrations of the known drug, thereby selecting for drug-resistant cells. Such drug-resistant cells survive in increased concentrations of the toxic drug by over-production of the enzyme which is inhibited by the drug, frequently as a result of amplification of the gene encoding the enzyme. Where drug resistance is caused by an increase in the copy number of the vector DNA encoding the inhibitable enzyme, there is a concomitant co-amplification of the vector DNA encoding the desired protein (TNF-R) in the host cell's DNA.

A preferred system for such co-amplification uses the gene for dihydrofolate reductase (DHFR), which can be inhibited by the drug methotrexate (MTX). To achieve co-amplification, a host cell which lacks an active gene encoding DHFR is either transformed with a vector which comprises DNA sequence encoding DHFR and a desired protein, or is co-transformed with a vector comprising a DNA sequence encoding DHFR and a vector comprising a DNA sequence encoding the desired protein. The transformed or co-transformed host cells are cultured in media containing increasing levels of MTX, and those cells lines which survive are selected.

A particularly preferred co-amplification system uses the gene for glutamine synthetase (GS), which is responsible for the synthesis of glutamate and ammonia using the hydrolysis of ATP to ADP and phosphate to drive the reaction. GS is subject to inhibition by a variety of inhibitors, for example methionine sulphoximine (MSX). Thus, TNF-R can be expressed in high concentrations by co-amplifying cells transformed with a vector comprising the DNA sequence for GS and a desired protein, or co-transformed with a vector comprising a DNA sequence encoding GS and a vector comprising a DNA sequence encoding the desired protein, culturing the host cells in media containing increasing levels of MSX and selecting for surviving cells. The GS co-amplification system, appropriate recombinant expression vectors and cells lines, are described in the following PCT applications: WO 87/04462, WO 89/01036, WO 89/10404 and WO 86/05807.

Recombinant proteins are preferably expressed by co-amplification of DHFR or GS in a mammalian host cell, such as Chinese Hamster Ovary (CHO) cells, or alternatively in a murine myeloma cell line, such as SP2/0-Ag14 or NS0 or a rat myeloma cell line, such as YB2/3.0-Ag20, disclosed in PCT applications WO/89/10404 and WO 86/05807.

A preferred eukaryotic vector for expression of TNF-R DNA is disclosed below in Example 2. This vector, referred to as pCAV/NOT, was derived from the mammalian high expression vector pDC201 and contains regulatory sequences from SV40, adenovirus-2, and human cytomegalovirus.

Purification of Recombinant TNF-R

Purified mammalian TNF receptors or analogs are prepared by culturing suitable host/vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts.

For example, supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. For example, a suitable affinity matrix can comprise a TNF or lectin or antibody molecule bound to a suitable support. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.

Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a TNF-R composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant mammalian TNF-R can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Fermentation of yeast which express mammalian TNF-R as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large-scale fermentation can be purified by

methods analogous to those disclosed by Urdal et al. (*J. Chromatog.* 296:171, 1984). This reference describes two sequential, reversed-phase HPLC steps for purification of recombinant human GM-CSF on a preparative HPLC column.

Human TNF-R synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which depend upon the purification steps taken to recover human TNF-R from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 1 percent by weight. Further, recombinant cell culture enables the production of TNF-R free of proteins which may be normally associated with TNF-R as it is found in nature in its species of origin, e.g. in cells, cell exudates or body fluids.

Therapeutic Administration of Recombinant Soluble TNF-R

The present invention provides methods of using therapeutic compositions comprising an effective amount of soluble TNF-R proteins and a suitable diluent and carrier, and methods for suppressing TNF-dependent inflammatory responses in humans comprising administering an effective amount of soluble TNF-R protein.

For therapeutic use, purified soluble TNF-R protein is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, soluble TNF-R protein compositions can be administered by bolus injection, continuous infusion, sustained release from implants, or other suitable technique. Typically, a soluble TNF-R therapeutic agent will be administered in the form of a composition comprising purified protein in conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the TNF-R with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate diluents. Preferably, product is formulated as a lyophilizate using appropriate excipient solutions (e.g., sucrose) as diluents. Appropriate dosages can be determined in trials. The amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.

Soluble TNF-R proteins are administered for the purpose of inhibiting TNF-dependent responses. A variety of diseases or conditions are believed to be caused by TNF, such as cachexia and septic shock. In addition, other key cytokines (IL-1, IL-2 and other colony stimulating factors) can also induce significant host production of TNF. Soluble TNF-R compositions may therefore be used, for example, to treat cachexia or septic shock or to treat side effects associated with cytokine therapy. Because of the primary roles IL-1 and IL-2 play in the production of TNF, combination therapy using both IL-1 receptors or IL-2 receptors may be preferred in the treatment of TNF-associated clinical indications.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

Example 1

Binding Assays

A. *Radiolabeling of TNFα and TNFβ.* Recombinant human TNF**α**, in the form of a fusion protein containing a hydrophilic octapeptide at the N-terminus, was expressed in yeast as a secreted protein and purified by affinity chromatography (Hopp et al., *Bio/Technology* 6:1204, 1988). Purified recombinant human TNF**β** was purchased from R&D Systems (Minneapolis, MN). Both proteins were radiolabeled using the commercially available solid phase agent, IODO-GEN (Pierce). In this procedure, 5 µg of

IODO-GEN were plated at the bottom of a 10 x 75 mm glass tube and incubated for 20 minutes at 4° C with 75 µl of 0.1 M sodium phosphate, pH 7.4 and 20 µl (2 mCi) Na ^{125}I. This solution was then transferred to a second glass tube containing 5 µg TNFα (or TNFβ) in 45 µl PBS for 20 minutes at 4° C. The reaction mixture was fractionated by gel filtration on a 2 ml bed volume of Sephadex G-25 (Sigma) equilibrated in Roswell Park Memorial Institute (RPMI) 1 640 medium containing 2.5% (w/v) bovine serum albumin (BSA), 0.2% (w/v) sodium azide and 20 mM Hepes pH 7.4 (binding medium). The final pool of ^{125}I-TNF was diluted to a working stock solution of 1 x 10^{-7} M in binding medium and stored for up to one month at 4° C without detectable loss of receptor binding activity. The specific activity is routinely 1 x 10^{6} cpm/mmole TNF.

B. *Binding to Intact Cells.* Binding assays with intact cells were performed by two methods. In the first method, cells were first grown either in suspension (e.g., U 937) or by adherence on tissue culture plates (e.g., WI26-VA4, COS cells expressing the recombinant TNF receptor). Adherent cells were subsequently removed by treatment with 5mM EDTA treatment for ten minutes at 37 degrees centigrade. Binding assays were then performed by a pthalate oil separation method (Dower et al., *J. Immunol. 132*:751, 1984) essentially as described by Park et al. (*J. Biol. Chem. 261*:4177, 1986). Non-specific binding of ^{125}I-TNF was measured in the presence of a 200-fold or greater molar excess of unlabeled TNF. Sodium azide (0.2%) was included in a binding assay to inhibit internalization of ^{125}I-TNF by cells. In the second method, COS cells transfected with the TNF-R-containing plasmid, and expressing TNF receptors on the surface, were tested for the ability to bind ^{125}I-TNF by the plate binding assay described by Sims et al. (*Science 241*:585, 1988).

C. *Solid Phase Binding Assays.* The ability of TNF-R to be stably adsorbed to nitrocellulose from detergent extracts of human cells yet retain TNF-binding activity provided a means of detecting TNF-R. Cell extracts were prepared by mixing a cell pellet with a 2 x volume of PBS containing 1% Triton X-100 and a cocktail of protease inhibitors (2 mM phenylmethyl sulfonyl fluoride, 10 µM pepstatin, 10 µM leupeptin, 2 mM o-phenanthroline and 2 mM EGTA) by vigorous vortexing. The mixture was incubated on ice for 30 minutes after which it was centrifuged at 12,000x g for 15 minutes at 8° C to remove nuclei and other debris. Two microliter aliquots of cell extracts were placed on dry BA85/21 nitrocellulose membranes (Schleicher and Schuell, Keene, NH) and allowed to dry. The membranes were incubated in tissue culture dishes for 30 minutes in Tris (0.05 M) buffered saline (0.15 M) pH 7.5 containing 3% w/v BSA to block nonspecific binding sites. The membrane was then covered with 5 x 10^{-11} M ^{125}I-TNF in PBS + 3% BSA and incubated for 2 hr at 4° C with shaking. At the end of this time, the membranes were washed 3 times in PBS, dried and placed on Kodak X-Omat AR film for 18 hr at -70° C.

Example 2

Isolation of Human TNF-R cDNA by Direct Expression of Active Protein in COS-7 Cells

Various human cell lines were screened for expression of TNF-R based on their ability to bind ^{125}I-labeled TNF. The human fibroblast cell line WI-26 VA4 was found to express a reasonable number of receptors per cell. Equilibrium binding studies showed that the cell line exhibited biphasic binding of ^{125}I-TNF with approximately 4,000 high affinity sites (K_a = 1 x 10^{10} M^{-1}) and 15,00 low affinity sites (K_a = 1 x 10^{8} M^{-1}) per cell.

An unsized cDNA library was constructed by reverse transcription of polyadenylated mRNA isolated from total RNA extracted from human fibroblast WI-26 VA4 cells grown in the presence of pokeweed mitogen using standard techniques (Gubler, et al., *Gene 25*:263, 1983; Ausubel et al., eds., *Current Protocols in Molecular Biology*, Vol. 1, 1987). The cells were harvested by lysing the cells in a guanidine hydrocnloride solution and total RNA isolated as previously described (March et al., *Nature 315*:641, 1985).

Poly A$^+$ RNA was isolated by oligo dT cellulose chromatography and double-stranded cDNA was prepared by a method similar to that of Gubler and Hoffman (*Gene 25*:263, 1983). Briefly, the poly A$^+$ RNA was converted to an RNA-cDNA hybrid by reverse transcriptase using oligo dT as a primer. The RNA-cDNA hybrid was then converted into double-stranded cDNA using RNAase H in combination with DNA polymerase I. The resulting double stranded cDNA was blunt-ended with T4 DNA polymerase. To the blunt-ended cDNA is added *EcoR*I linker-adapters (having internal *Not*I sites) which were phosphorylated on only one end (Invitrogen). The linker-adaptered cDNA was treated with T4 polynucleotide kinase to phosphorylate the 5' overhanging region of the linker-adapter and unligated linkers were removed by

running the cDNA over a Sepharose CL4B column. The linker-adapted cDNA was ligated to an equimolar concentration of *EcoR*1 cut and dephosphorylated arms of bacteriophage λgt10 (Huynh et al. *DNA Cloning: A Practical Approach*. Glover, ed., IRL Press, pp. 49-78). The ligated DNA was packaged into phage particles using a commercially available kit to generate a library of recombinants (Stratagene Cloning Systems, San Diego, CA, USA). Recombinants were further amplified by plating phage on a bacterial lawn of *E. coli* strain c600(hfl⁻).

Phage DNA was purified from the resulting λgt10 cDNA library and the cDNA inserts excised by digestion with the restriction enzyme *Not*1. Following electrophoresis of the digest through an agarose gel, cDNAs greater than 2,000 bp were isolated.

The resulting cDNAs were ligated into the eukaryotic expression vector pCAV NOT, which was designed to express cDNA sequences inserted at its multiple cloning site when transfected into mammalian cells. pCAV/NOT was assembled from pDC201 (a derivative of pMLSV, previously described by Cosman et al., *Nature 312*: 768, 1984), SV40 and cytomegalovirus DNA and comprises, in sequence with the direction of transcription from the origin of replication: (1) SV40 sequences from coordinates 5171-270 including the origin of replication, enhancer sequences and early and late promoters; (2) cytomegalovirus sequences including the promoter and enhancer regions (nucleotides 671 to +63 from the sequence published by Boechart et al. (*Cell 41*:521, 1985); (3) adenovirus-2 sequences containing the first exon and part of the intron between the first and second exons of the tripartite leader, the second exon and part of the third exon of the tripartite leader and a multiple cloning site (MCS) containing sites for Xho1, Kpn1, Sma1, Not1 and *Bgl*1; (4) SV40 sequences from coordinates 4127-4100 and 2770-2533 that include the polyadenylation and termination signals for early transcription; (5) sequences derived from pBR322 and virus-associated sequences VAI and VAII of pDC201, with adenovirus sequences 10532-11156 containing the VAI and VAII genes, followed by pBR322 sequences from 4363-2486 and 1094-375 containing the ampicillin resistance gene and origin of replication.

The resulting WI-26 VA4 cDNA library in pCAV/NOT was used to transform *E. coli* strain DH5α, and recombinants were plated to provide approximately 800 colonies per plate and sufficient plates to provide approximately 50,000 total colonies per screen. Colonies were scraped from each plate, pooled, and plasmid DNA prepared from each pool. The pooled DNA was then used to transfect a sub-confluent layer of monkey COS-7 cells using DEAE-dextran followed by chloroquine treatment, as described by Luthman et al. (*Nucl. Acids Res. 11*:1295, 1983) and McCutchan et al. (*J. Natl. Cancer Inst. 41*:351, 1986). The cells were then grown in culture for three days to permit transient expression of the inserted sequences. After three days, cell culture supernatants were discarded and the cell monolayers in each plate assayed for TNF binding as follows. Three ml of binding medium containing 1.2 x 10^{-11} M ^{125}I-labeled FLAG®-TNF was added to each plate and the plates incubated at 4°C for 120 minutes. This medium was then discarded, and each plate was washed once with cold binding medium (containing no labeled TNF) and twice with cold PBS. The edges of each plate were then broken off, leaving a flat disk which was contacted with X-ray film for 72 hours at -70°C using an intensifying screen. TNF binding activity was visualized on the exposed films as a dark focus against a relatively uniform background.

After approximately 240,000 recombinants the library had been screened in this manner, one transfectant pool was observed to provide TNF binding foci which were clearly apparent against the background exposure.

A frozen stock of bacteria from the positive pool was then used to obtain plates of approximately 150 colonies. Replicas of these plates were made on nitrocellulose filters, and the plates were then scraped and plasmid DNA prepared and transfected as described above to identify a positive plate. Bacteria from individual colonies from the nitrocellulose replica of this plate were grown in 0.2 ml cultures, which were used to obtain plasmid DNA, which was transfected into COS-7 cells as described above. In this manner, a single clone, clone 1, was isolated which was capable of inducing expression of human TNF-R in COS cells. The expression vector pCAV/NOT containing the TNF-R cDNA clone 1 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA (Accession No. 68088) under the name pCAV-NOT-TNF-R, on 6th Sept. 1989.

Example 3

Construction of cDNAs Encoding Soluble huTNF-RΔ235

A cDNA encoding a soluble huTNF-RΔ235 (having the sequence of amino acids 1-235 of Figure 2A) was constructed by excising an 840 bp fragment from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Pvu2. Not1 cuts at the multiple cloning site of pCAV/NOT-TNF-R and Pvu2 cuts within the TNF-R coding region 20 nucleotides 5′ of the transmembrane region. In order to reconstruct the 3′ end of the TNF-R sequences, two oligonucleotides were synthesized and annealed to create the following oligonucleotice linker:

```
          Pvu2                          BamH1 Bgl2
          CTGAAGGGAGCACTGGCGACTAAGGATCCA
          GACTTCCCTCGTGACCGCTGATTCCTAGGTCTAG
        AlaGluGlySerThrGlyAspEnd
```

This oligonucleotide linker has terminal Pvu2 and Bgl2 restriction sites, regenerates 20 nucleotides of the TNF-R, followed by a termination codon (underlined) and a BamH1 restriction site (for convenience in isolating the entire soluble TNF-R by Not1/BamH1 digestion). This oligonucleotide was then ligated with the 840 bp Not1 Pvu2 TNF-R insert into Bgl2/Not1 cut pCAV/NOT to yield psolhuTNF-RΔ235/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF.

Example 4

Construction of cDNAs Encoding Soluble huTNF-RΔ185

A cDNA encoding a soluble huTNF-RΔ185 (having the sequence of amino acids 1-185 of Figure 2A) was constructed by excising a 640 bp fragment from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Bgl2. Not1 cuts at the multiple cloning site of pCAV/NO-TNF-R and Bgl2 cuts within the TNF-R coding region at nucleotide 637, which is 237 nucleotides 5′ of the transmembrane region. The following oligonucleotide linkers were synthesized:

```
          Bgl2
5'-GATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGC-3'
       ACATTGCACCACCGGTAGGGACCCTTACGTTCG
   IleCysAsnValValAlaIleProGlyAsnAlaSerMetAspAla

                                                Not1
5'-        AGTCTGCACGTCCACGTCCCCCACCCGGTGAGC    -3'
   TACCTACGTCAGACGTGCAGGTGCAGGGGGTGGGCCACTCGCCGG
            ValCysThrSerThrSerProThrArgEnd
```

The above oligonucleotide linkers reconstruct the 3′ end of the receptor molecule up to nucleotide 708, followed by a termination codon (underlined). These oligonucleotides were then ligated with the 640 bp Not1 TNF-R insert into Not1 cut pCAV/NOT to yield the expression vector psolTNFRΔ185/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF.

Example 5

Construction of cDNAs Encoding Soluble huTNF-RΔ163

A cDNA encoding a soluble huTNF-RΔ163 (having the sequence of amino acids 1-163 of Figure 2A) was constructed by excising a 640 bp fragment from from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Bgl2 as described in Example 4. The following oligonucleotide linkers were synthesized:

```
          Bgl2          Not1
5'-GATCTGTTGAGC       -3'
       ACAACTCGCCGG
    IleCysEnd
```

This above oligonucleotide linker reconstructs the 3′ end of the receptor molecule up to nucleotide 642 (amino acid 163), followed by a termination codon (underlined). This oligonucleotide was then ligated with the 640 bp Not1 TNF-R insert into Not1 cut pCAV/NOT to yield the expression vector psolTNFRΔ163/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF in the binding assay described in Example 1.

Example 6

Construction of cDNAs Encoding Soluble huTNF-RΔ142

A cDNA encoding a soluble huTNF-RΔ142 (having the sequence of amino acids 1-142 of Figure 2A) was constructed by excising a 550 bp fragment from from pCAV/NOT-TNF-R with the restriction enzymes Not1 and AlwN1. AlwN1 cuts within the TNF-R coding region at nucleotide 549. The following oligonucleotide linker was synthesized:

```
          Bgl2          Not1
5'-CTGAAACATCAGACGTGGTGTGCAAGCCCTGTTAAA-3'
CTTGACTTTGTAGTCTGCACCACACGTTCGGGACAATTTCTAGA
                                    End
```

This above oligonucleotide linker reconstructs the 3′ end of the receptor molecule up to nucleotide 579 (amino acid 142), followed by a termination codon (underlined). This oligonucleotide was then ligated with the 550 bp Not1/AlwN1 TNF-R insert into Not1/Bgl2 cut pCAV/NOT to yield the expression vector psolTNFRΔ142/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector did not induced expression of soluble human TNF-R which was capable of binding TNF. It is believed that this particular construct failed to express biologically active TNF-R because one or more essential cysteine residue (e.g., Cys^{157} or Cys^{163}) required for intramolecular bonding (for formation of the proper tertiary structure of the TNF-R molecule) was eliminated.

Example 7

Expression of Soluble TNF Receptors in CHO Cells

Soluble TNF receptor was expressed in Chinese Hamster Ovary (CHO) cells using the glutamine-synthetase (GS) gene amplification system, substantially as described in PCT patent application Nos. WO87/04462 and WO89/01036. Briefly, CHO cells are transfected with an expression vector containing genes for both TNF-R and GS. CHO cells are selected for GS gene expression based on the ability of the transfected DNA to confer resistance to low levels of methionine sulphoximine (MSX). GS sequence amplification events in such cells are selected using elevated MSX concentrations In this way, contiguous

TNF-R sequences are also amplified and enhanced TNF-R expression is achieved.

The vector used in the GS expression system was psolTNFR/P6/PSVLGS, which was constructed as follows. First, the vector pSVLGS.1 (described in PCT Application Nos. WO87/04462 and WO89/01036, and available from Celltech, Ltd., Berkshire, UK) was cut with the BamH1 restriction enzyme and dephosphorylated with calf intestinal alkaline phosphatase (CIAP) to prevent the vector from religating to itself. The BamH1 cut pSVLGS.1 fragment was then ligated to a 2.4 kb BamH1 to Bgl2 fragment of pEE6hCMV (described in PCT Application No. WO89/01036, also available from Celltech) which was cut with Bgl2, BamH1 and Fsp1 to avoid two fragments of similar size, to yield an 11.2 kb vector designated p6/PSVLGS.1. pSVLGS.1 contains the glutamine synthetase selectable marker gene under control of the SV40 later promoter. The BamH1 to Bgl2 fragment of pEE6hCMV contains the human cytomegalovirus major immediate early promoter (hCMV), a polylinker, and the SV40 early polyadenylation signal. The coding sequences for soluble TNF-R were added to p6/PSVLGS.1 by excising a Not1 to BamH1 fragment from the expression vector psolTNFR/CAVNOT (made according to Example 3 above), blunt ending with Klenow and ligating with Sma1 cut dephosphorylated p6/PSVLGS.1, thereby placing the solTNF-R coding sequences under the control of the hCMV promoter. This resulted in a single plasmid vector in which the SV40/GS and hCMB/solTNF-R transcription units are transcribed in opposite directions. This vector was designated psolTNFR/P6/PSVLGS.

psolTNFR/P6/PSVLGS was used to transfect CHO-K1 cells (available from ATCC, Rochville, MD, under accession number CCL 61) as follows. A monolayer of CHO-K1 cells were grown to subconfluency in Minimum Essential Medium (MEM) 10X (Gibco: 330-1581AJ) without glutamine and supplemented with 10% dialysed fetal bovine serum (Gibco: 220-6300AJ), 1 mM sodium pyruvate (Sigma), MEM non-essential amino acids (Gibco: 320-1140AG), 500 µM asparagine and glutamate (Sigma) and nucleosides (30 µM adenosine, guanosine, cytidine and uridine and 10 µM thymidine)(Sigma).

Approximately 1 x 10^6 cells per 10 cm petri dish were transfected with 10 ug of psolTNFR/P6/PSVLGS by standard calcium phosphate precipitation, substantially as described by Graham & van der Eb, *Virology* 52:456 (1983). Cells were subjected to glycerol shock (15% glycerol in serum-free culture medium for approximately 1.5 minutes) approximately 4 hours after transfection, substantially as described by Frost & Williams, *Virology* 91:39 (1978), and then washed with serum-free medium. One day later, transfected cells were fed with fresh selective medium containing MSX at a final concentration of 25 uM. Colonies of MSX-resistant surviving cells were visible within 3-4 weeks. Surviving colonies were transferred to 24-well plates and allowed to grow to confluency in selective medium. Conditioned medium from confluent wells were then assayed for soluble TNF-R activity using the binding assay described in Example 1 above. These assays indicated that the colonies expressed biologically active soluble TNF-R.

In order to select for GS gene amplification, several MSX-resistant cell lines are transfected with psolTNFR/P6/PSVLGS and grown in various concentrations of MSX. For each cell line, approximately 1x10^6 cells are plated in gradually increasing concentrations of 100 uM, 250 uM, 500 uM and 1 mM MSX and incubated for 10-14 days. After 12 days, colonies resistant to the higher levels of MSX appear. The surviving colonies are assayed for TNF-R activity using the binding assay described above in Example 1. Each of these highly resistant cell lines contains cells which arise from multiple independent amplification events. From these cells lines, one or more of the most highly resistant cells lines are isolated. The amplified cells with high production rates are then cloned by limiting dilution cloning. Mass cell cultures of the transfectants secrete active soluble TNF-R.

Example 8

Expression of Soluble Human TNF-R in Yeast

Soluble human TNF-R was expressed in yeast with the expression vector pIXY432, which was derived from the yeast expression vector pIXY120 and plasmid pYEP352. pIXY120 is identical to pYαHuGM (ATCC 53157), except that it contains no cDNA insert and includes a polylinker/multiple cloning site with a Nco1 restriction site.

A DNA fragment encoding TNF receptor and suitable for cloning into the yeast expression vector pIXY120 was first generated by polymerase chain reaction (PCR) amplification of the extracellular portion of the full length receptor from pCAV/NOT-TNF-R (ATCC 68088). The following primers were used in this PCR

amplification:

5' End Primer

```
5'-TTCCGGTACCTTTGGATAAAAGAGACTACAAGGAC
   Asp718->ProLeuAspLysArgAspTyrLysAsp

      GACGATGACAAGTTGCCCGCCCAGGTGGCATTTACA-3'
      AspAspAspLys<-------- TNF-R ---------->
```

3' End Primer (antisense)

```
5'-CCCGGGATCCTTAGTCGCCAGTGCTCCCTTCAGCTGGG-3'
      BamH1>End<-----------TNF-R---------->
```

The 5' end oligonucleotide primer used in the amplification included an Asp718 restriction site at its 5' end, followed by nucleotides encoding the 3' end of the yeast α-factor leader sequence (Pro-Leu-Asp-Lys-Arg) and those encoding the 8 amino acids of the FLAG® peptide (AspTyrLysAspAspAspAspLys) fused to sequence encoding the 5' end of the mature receptor. The FLAG® peptide (Hopp et al., *Bio/Technology* 6:1204, 1988) is a highly antigenic sequence which reversibly binds the monoclonal antibody M1 (ATCC HB 9259). The oligonucleotide used to generate the 3' end of the PCR-derived fragment is the *antisense* strand of DNA encoding sequences which terminate the open reading frame of the receptor after nucleotide 704 of the mature coding region (following the Asp residue preceding the transmembrane domain) by introducing a TAA stop codon (underlined). The stop codon is then followed by a BamH1 restriction site. The DNA sequences encoding TNF-R are then amplified by PCR, substantially as described by Innis et al., eds., *PCR Protocols: A Guide to Methods and Applications* (Academic Press, 1990).

The PCR-derived DNA fragment encoding soluble human TNF-R was subcloned into the yeast expression vector pIXY120 by digesting the PCR-derived DNA fragment with BamH1 and Asp718 restriction enzymes, digesting pIXY120 with BamH1 and Asp718, and ligating the PCR fragment into the cut vector *in vitro* with T4 DNA ligase. The resulting construction (pIXY424) fused the open reading frame of the FLAG®-soluble TNF receptor in-frame to the complete α-factor leader sequence and placed expression in yeast under the aegis of the regulated yeast alcohol dehydrogenase (ADH2) promoter. Identity of the nucleotide sequence of the soluble TNF receptor carried in pIXY424 with those in cDNA clone 1 were verified by DNA sequencing using the dideoxynucleotide chain termination method. pIXY424 was then transformed into *E. coli* strain RR1.

Soluble human TNF receptor was also expressed and secreted in yeast in a second vector. This second vector was generated by recovering the pIXY424 plasmid from *E. coli* and digesting with EcoR1 and BamH1 restriction enzymes to isolate the fragment spanning the region encoding the ADH2 promoter, the α-factor leader, the FLAG®-soluble TNF receptor and the stop codon. This fragment was ligated *in vitro* into EcoR1 and BamH1 cut plasmid pYEP352 (Hill et al., *Yeast* 2:163 (1986)), to yield the expression plasmid pIXY432, which was transformed into *E.coli* strain RR1.

To assess secretion of the soluble human TNF receptor from yeast, pIXY424 was purified and introduced into a diploid yeast strain of *S. cerevisiae* (XV2 181) by electroporation and selection for acquisition of the plasmid-borne yeast TRP1$^+$ gene on media lacking tryptophan. To assess secretion of the receptor directed by pIXY432, the plasmid was introduced into the yeast strain PB149-6b by electroporation followed by selection for the plasmid-borne URA3$^+$ gene with growth on media lacking uracil. Overnight cultures were grown at 30°C in the appropriate selective media. The PB149-6b/pIXY434 transformants were diluted into YEP-1% glucose media and grown at 30°C for 38-40 hours. Supernatants were prepared by removal of cells by centrifugation, and filtration of supernatants through 0.45μ filters.

The level of secreted receptor in the supernatants was determined by immuno-dotblot. Briefly, 1 ul of supernatants, and dilutions of the supernatants, were spotted onto nitrocellulose filters and allowed to dry. After blocking non-specific protein binding with a 3% BSA solution, the filters were incubated with diluted M1 anti-FLAG® antibody, excess antibody was removed by washing and then dilutions of horseradish peroxidase conjugated anti-mouse IgG antibodies were incubated with the filters. After removal of excess secondary antibodies, peroxidase substrates were added and color development was allowed to proceed for approximately 10 minutes prior to removal of the substrate solution.

The anti-FLAG® reactive material found in the supernatants demonstrated that significant levels of

receptor were secreted by both expression systems. Comparisons demonstrated that the pIXY432 system secreted approximately 8-16 times more soluble human TNF receptor than the pIXY424 system. The supernatants were assayed for soluble TNF-R activity, as described in Example 1, by their ability to bind ^{125}I-TNFα and block TNFα binding. The pIXY432 supernatants were found to contain significant levels of active soluble TNF-R.

Example 9

Isolation of Murine TNF-R cDNAs

Murine TNF-R cDNAs were isolated from a cDNA library made from murine 7B9 cells, an antigen-dependent helper T cell line derived from C57BL/6 mice, by cross-species hybridization with a human TNF-R probe. The cDNA library was constructed in λZAP (Stratagene, San Diego), substantially as described above in Example 2, by isolating polyadenylated RNA from the 7B9 cells.

A double-stranded human TNF-R cDNA probe was produced by excising an approximately 3.5 kb Not1 fragment of the human TNF-R clone 1 and ^{32}P-labeling the cDNA using random primers (Boehringer-Mannheim).

The murine cDNA library was amplified once and a total of 900,000 plaques were screened, substantially as described in Example 2, with the human TNF-R cDNA probe. Approximately 21 positive plaques were purified, and the Bluescript plasmids containing EcoR1-linkered inserts were excised (Stratagene, San Diego). Nucleic acid sequencing of a portion of murine TNF-R clone 11 indicated that the coding sequence of the murine TNF-R was approximately 88% homologous to the corresponding nucleotide sequence of human TNF-R. A partial nucleotide sequence of murine TNF-R cDNA clone 11 is set forth in Figures 3A-3B.

Example 10

Preparation of Monoclonal Antibodies to TNF-R

Preparations of purified recombinant TNF-R, for example, human TNF-R, or transfected COS cells expressing high levels of TNF-R are employed to generate monoclonal antibodies against TNF-R using conventional techniques, for example, those disclosed in U.S. Patent 4,411,993. Such antibodies likely to be useful in interfering with TNF binding to TNF receptors, for example, in ameliorating toxic or other undesired effects of TNF, or as components of diagnostic or research assays for TNF or soluble TNF receptor.

To immunize mice, TNF-R immunogen is emulsified in complete Freund's adjuvant and injected in amounts ranging from 10-100 µg subcutaneously into Balb/c mice. Ten to twelve days later, the immunized animals are boosted with additional immunogen emulsified in incomplete Freund's adjuvant and periodically boosted thereafter on a weekly to biweekly immunization schedule. Serum samples are periodically taken by retro-orbital bleeding or tail-tip excision for testing by dot-blot assay (antibody sandwich) or ELISA (enzyme-linked immunosorbent assay). Other assay procedures are also suitable. Following detection of an appropriate antibody titer, positive animals are given an intravenous injection of antigen in saline. Three to four days later, the animals are sacrificed, splenocytes harvested, and fused to the murine myeloma cell line NS1. Hybridoma cell lines generated by this procedure are plated in multiple microtiter plates in a HAT selective medium (hypoxanthine, aminopterin, and thymidine) to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

Hybridoma clones thus generated can be screened by ELISA for reactivity with TNF-R, for example, by adaptations of the techniques disclosed by Engvall et al., *Immunochem.* 8:871 (1971) and in U.S. Patent 4,703,004. Positive clones are then injected into the peritoneal cavities of syngeneic Balb/c mice to produce ascites containing high concentrations (>1 mg/ml) of anti-TNF-R monoclonal antibody. The resulting monoclonal antibody can be purified by ammonium sulfate precipitation followed by gel exclusion

chromatography, and/or affinity chromatography based on binding of antibody to Protein A of *Staphylococcus aureus*.

Claims

1. An isolated DNA sequence encoding a biologically active mammalian TNF receptor (TNF-R) protein.
2. An isolated DNA sequence according to claim 1, selected from the group consisting of:
   (a) cDNA clones having a nucleotide sequence derived from the coding region of a native mammalian TNF-R gene;
   (b) DNA sequences capable of hybridization to the clones of (a) under moderately stringent conditions (50 °C, 2 x SSC) and which encode biologically active TNF-R protein; and
   (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R protein.
3. An isolated DNA sequence according to claim 1 which encodes a soluble human TNF-R protein.
4. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein has an amino acid sequence comprises the sequence of amino acid residues 1-x of Figure 2A, wherein x is selected from the group consisting of amino acids 163-235
5. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-235 of Figure 2A.
6. A DNA sequence according to claim 5, wherein amino acid residue 46 is selected from the group consisting of Ile and Thr and amino acid residue 118 is selected from the group consisting of Val and Ile.
7. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-185 of Figure 2A.
8. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-163 of Figure 2A.
9. A recombinant expression vector comprising a DNA sequence according to any one of claims 1-8.
10. A process for preparing a biologically active mammalian TNF receptor (TNF-R) protein, comprising culturing a suitable host cell comprising a vector according to claim 8 under conditions promoting expression.
11. A purified biologically active mammalian TNF receptor (TNF-R) protein.
12. A purified biologically active soluble human TNF-R protein.
13. A purified biologically active TNF-R protein according to claim 12, comprising the sequence of amino acid residues 1-235 of Figure 2A.
14. A purified biologically active TNF-R protein according to claim 12, comprising the sequence of amino acid residues 1-185 of Figure 2A.
15. A purified biologically active TNF-R protein according to claim 12, comprising the sequence of amino acid residues 1-163 of Figure 2A.
16. The use of a mammalian TNF-R protein in preparing a medicament for regulating immune responses in mammals.
17. The method of claim 16, wherein the TNF-R protein is human TNF-R and the mammal to be treated is a human.
18. The use of mammalian TNF-R protein in preparing a pharmaceutical composition suitable for parenteral administration to a human patient for regulating immune responses.
19. A process for detecting TNF or TNF-R molecules or the interaction thereof, comprising use of a mammalian TNF receptor protein, a soluble TNF receptor protein capable of binding TNF or substantially similar TNF-R analog produced by recombinant cell culture.
20. Antibodies immunoreactive with mammalian TNF receptors.

Claims for the following Contracting State: ES

1. A process for preparing a purified mammalian TNF receptor (TNF-R) protein, the process comprising coupling together successive amino acid residues by the formation of peptide bonds to form a TNF-R polypeptide.
2. A process according to claim 1, wherein the TNF-R protein is a soluble human TNF-R protein.
3. A process according to claim 2, wherein the soluble TNF-R protein has an amino acid sequence comprising the sequence of amino acid residues 1-x of Figure 2A, wherein x is selected from the group consisting of amino acids 163-235.

4. A process according to claim 3, wherein the soluble TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1-235 of Figure 2A.

5. A process according to claim 3, wherein the soluble TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1-185 of Figure 2A.

6. A process according to claim 3, wherein the soluble TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1-163 of Figure 2A.

7. The use of a mammalian TNF-R protein in preparing a medicament for regulating immune responses in mammals.

8. The use of a mammalian TNF-R protein in preparing a pharmaceutical composition suitable for parenteral administration to a human patient for regulating immune responses.

9. A process for preparing a DNA sequence encoding a mammalian TNF receptor (TNF-R) protein, the process comprising coupling together successive nucleotide residues.

10. A process for preparing a DNA sequence according to claim 9, wherein the DNA sequence encodes a soluble human TNF-R protein.

11. A process for preparing a DNA sequence according to claim 10, wherein the DNA sequence encodes a soluble TNF-R protein having an amino acid sequence comprising the sequence of amino acid residues 1-x of Figure 2A, wherein x is selected from the group consisting of amino acids 163-235.

12. A process for preparing a DNA sequence according to claim 10, wherein the DNA sequence encodes a soluble TNF-R protein having an amio acid sequence which comprises the sequence of amino acid residues 1-235 of Figure 2A.

13. A process for preparing a DNA sequence according to claim 10, wherein the DNA sequence encodes a soluble TNF-R protein having an amio acid sequence which comprises the sequence of amino acid residues 1-185 of Figure 2A.

14. A process for preparing a DNA sequence according to claim 10, wherein the DNA sequence encodes a soluble TNF-R protein having an amio acid sequence which comprises the sequence of amino acid residues 1-163 of Figure 2A.

15. A process for preparing a DNA sequence according to claim 9, said DNA being selected from the group consisting of:

(a) cDNA clones having a nucleotide sequence derived from the coding region of a native mammalian TNF-R gene;

(b) DNA sequences capable of hybridization to the clones of (a) under moderately stringent conditions (50 °C, 2 x SSC) and which encode biologically active TNF-R protein; and

(c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R protein.

16. A process for preparing a DNA sequence according to claim 9, said DNA encoding a TNF-R protein having the sequence of amino acids of the TNF-R protein expressed by pCAV/NOT-TNF-R (ATCC 68088).

17. A process for preparing a recombinant expression vector, comprising ligating bacterial, yeast or mammalian expression vector DNA and a DNA sequence encoding a human TNF-R protein sequence.

18. A process for preparing a mammalian TNF-R or an analog thereof, comprising culturing a suitable host cell comprising a vector prepared according to claim 17 under conditions promoting expression.

19. A process for detecting TNF or TNF-R protein molecules or the interaction thereof, comprising use of a mammalian TNF-R protein, a soluble TNF-R protein capable of binding TNF or substantially similar TNF-R analog produced by recombinant cell culture.

20. A process for the preparation of antibodies immunoreactive with TNF receptor, the process comprising either (a) culturing a hybridoma cell expressing the antibodies and harvesting the antibodies, or (b) harvesting antibodies immunoreactive with TNF receptor from an appropriately immunised animal.

Claims for the following Contracting State: GR

1. An isolated DNA sequence encoding a biologically active mammalian TNF receptor (TNF-R) protein.

2. An isolated DNA sequence according to claim 1, selected from the group consisting of:

(a) cDNA clones having a nucleotide sequence derived from the coding region of a native mammalian TNF-R gene;

(b) DNA sequences capable of hybridization to the clones of (a) under moderately stringent conditions (50 °C, 2 x SSC) and which encode biologically active TNF-R protein; and

(c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R protein.

3. An isolated DNA sequence according to claim 1 which encodes a soluble human TNF-R protein.

4. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein has an amino acid sequence comprising the sequence of amino acid residues 1-x of Figure 2A, wherein x is selected from the group consisting of amino acids 163-235.

5. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-235 of Figure 2A.

6. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-185 of Figure 2A.

7. An isolated DNA sequence according to claim 3, wherein the soluble human TNF-R protein comprises the sequence of amino acids 1-163 of Figure 2A.

8. A DNA sequence according to claim 3, wherein amino acid residue 46 is selected from the group consisting of Ile and Thr and amino acid residue 118 is selected from the group consisting of Val and Ile.

9. A recombinant expression vector comprising a DNA sequence according to any one of claims 1-7.

10. A process for preparing a purified mammalian TNF receptor (TNF-R) protein, the process comprising coupling together successive amino acid residues by the formation of peptide bonds to form a TNF-R polypeptide.

11. A process according to claim 9, wherein the TNF-R protein is a soluble human TNF-R protein.

12. A process according to claim 11, wherein the soluble human TNF-R protein has an amino acid sequence comprising the sequence of amino acid residues 1-x of Figure 2A, wherein x is selected from the group consisting of amino acids 163-235.

13. A process according to claim 11, wherein the soluble human TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1 -235 of Figure 2A.

14. A process according to claim 11, wherein the soluble human TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1-185 of Figure 2A.

15. A process according to claim 11, wherein the soluble human TNF-R protein has an amio acid sequence which comprises the sequence of amino acid residues 1-163 of Figure 2A.

16. The use of a mammalian TNF-R protein in preparing a medicament for regulating immune responses in mammals.

17. The use of a mammalian TNF-R protein in preparing a pharmaceutical composition suitable for parenteral administration to a human patient for regulating immune responses.

18. Antibodies immunoreactive with mammalian TNF receptors.

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1641 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(G) CELL TYPE: Fibroblast
(H) CELL LINE: WI-26 VA4

(vii) IMMEDIATE SOURCE:
(A) LIBRARY: WI-26 VA4
(B) CLONE: 1

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 88..1473
(D) OTHER INFORMATION:
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 88..1470
(D) OTHER INFORMATION:
(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: 88..153
(D) OTHER INFORMATION:

(x) PUBLICATION INFORMATION:
(A) AUTHORS: Smith , Craig A.
Davis, Terri
Anderson, Dirk
Solam, Lisabeth
Beckmann, M. P.
Jerzy, Rita
Dower, Steven K.
Cosman, David
Goodwin, Raymond G.
(B) TITLE: A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins
(C) JOURNAL: Science
(D) VOLUME: 248
(F) PAGES: 1019-1023
(G) DATE: 25-MAY-1990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GCGAGGCAGG CAGCCTGGAG AGAAGGCGCT GGGCTGCGAG GGCGCGAGGG CGCGAGGGCA      60

GGGGGCAACC GGACCCCGCC CGCATCC ATG GCG CCC GTC GCC GTC TGG GCC          111
                                Met Ala Pro Val Ala Val Trp Ala
                                  1               5

GCG CTG GCC GTC GGA CTG GAG CTC TGG GCT GCG GCG CAC GCC TTG CCC        159
Ala Leu Ala Val Gly Leu Glu Leu Trp Ala Ala Ala His Ala Leu Pro
    10                  15                  20
```

```
GCC CAG GTG GCA TTT ACA CCC TAC GCC CCG GAG CCC GGG AGC ACA TGC          207
Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys
 25                  30                  35                  40

CGG CTC AGA GAA TAC TAT GAC CAG ACA GCT CAG ATG TGC TGC AGC AAA          255
Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys
                 45                  50                  55

TGC TCG CCG GGC CAA CAT GCA AAA GTC TTC TGT ACC AAG ACC TCG GAC          303
Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp
             60                  65                  70

ACC GTG TGT GAC TCC TGT GAG GAC AGC ACA TAC ACC CAG CTC TGG AAC          351
Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn
         75                  80                  85

TGG GTT CCC GAG TGC TTG AGC TGT GGC TCC CGC TGT AGC TCT GAC CAG          399
Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln
     90                  95                  100

GTG GAA ACT CAA GCC TGC ACT CGG GAA CAG AAC CGC ATC TGC ACC TGC          447
Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys
105                 110                 115                 120

AGG CCC GGC TGG TAC TGC GCG CTG AGC AAG CAG GAG GGG TGC CGG CTG          495
Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu
                125                 130                 135

TGC GCG CCG CTG CGC AAG TGC CGC CCG GGC TTC GGC GTG GCC AGA CCA          543
Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala Arg Pro
            140                 145                 150

GGA ACT GAA ACA TCA GAC GTG GTG TGC AAG CCC TGT GCC CCG GGG ACG          591
Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr
        155                 160                 165

TTC TCC AAC ACG ACT TCA TCC ACG GAT ATT TGC AGG CCC CAC CAG ATC          639
Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile
    170                 175                 180

TGT AAC GTG GTG GCC ATC CCT GGG AAT GCA AGC ATG GAT GCA GTC TGC          687
Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys
185                 190                 195                 200

ACG TCC ACG TCC CCC ACC CGG AGT ATG GCC CCA GGG GCA GTA CAC TTA          735
Thr Ser Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu
                205                 210                 215

CCC CAG CCA GTG TCC ACA CGA TCC CAA CAC ACG CAG CCA ACT CCA GAA          783
Pro Gln Pro Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu
            220                 225                 230

CCC AGC ACT GCT CCA AGC ACC TCC TTC CTG CTC CCA ATG GGC CCC AGC          831
Pro Ser Thr Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser
        235                 240                 245

CCC CCA GCT GAA GGG AGC ACT GGC GAC TTC GCT CTT CCA GTT GGA CTG          879
Pro Pro Ala Glu Gly Ser Thr Gly Asp Phe Ala Leu Pro Val Gly Leu
    250                 255                 260

ATT GTG GGT GTG ACA GCC TTG GGT CTA CTA ATA ATA GGA GTG GTG AAC          927
Ile Val Gly Val Thr Ala Leu Gly Leu Leu Ile Ile Gly Val Val Asn
265                 270                 275                 280
```

```
TGT GTC ATC ATG ACC CAG GTG AAA AAG AAG CCC TTG TGC CTG CAG AGA        975
Cys Val Ile Met Thr Gln Val Lys Lys Lys Pro Leu Cys Leu Gln Arg
                285                 290                 295

GAA GCC AAG GTG CCT CAC TTG CCT GCC GAT AAG GCC CGG GGT ACA CAG       1023
Glu Ala Lys Val Pro His Leu Pro Ala Asp Lys Ala Arg Gly Thr Gln
            300                 305                 310

GGC CCC GAG CAG CAG CAC CTG CTG ATC ACA GCG CCG AGC TCC AGC AGC       1071
Gly Pro Glu Gln Gln His Leu Leu Ile Thr Ala Pro Ser Ser Ser Ser
        315                 320                 325

AGC TCC CTG GAG AGC TCG GCC AGT GCG TTG GAC AGA AGG GCG CCC ACT       1119
Ser Ser Leu Glu Ser Ser Ala Ser Ala Leu Asp Arg Arg Ala Pro Thr
    330                 335                 340

CGG AAC CAG CCA CAG GCA CCA GGC GTG GAG GCC AGT GGG GCC GGG GAG       1167
Arg Asn Gln Pro Gln Ala Pro Gly Val Glu Ala Ser Gly Ala Gly Glu
345                 350                 355                 360

GCC CGG GCC AGC ACC GGG AGC TCA GAT TCT TCC CCT GGT GGC CAT GGG       1215
Ala Arg Ala Ser Thr Gly Ser Ser Asp Ser Ser Pro Gly Gly His Gly
                365                 370                 375

ACC CAG GTC AAT GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC TCT GAC       1263
Thr Gln Val Asn Val Thr Cys Ile Val Asn Val Cys Ser Ser Ser Asp
            380                 385                 390

CAC AGC TCA CAG TGC TCC TCC CAA GCC AGC TCC ACA ATG GGA GAC ACA       1311
His Ser Ser Gln Cys Ser Ser Gln Ala Ser Ser Thr Met Gly Asp Thr
        395                 400                 405

GAT TCC AGC CCC TCG GAG TCC CCG AAG GAC GAG CAG GTC CCC TTC TCC       1359
Asp Ser Ser Pro Ser Glu Ser Pro Lys Asp Glu Gln Val Pro Phe Ser
    410                 415                 420

AAG GAG GAA TGT GCC TTT CGG TCA CAG CTG GAG ACG CCA GAG ACC CTG       1407
Lys Glu Glu Cys Ala Phe Arg Ser Gln Leu Glu Thr Pro Glu Thr Leu
425                 430                 435                 440

CTG GGG AGC ACC GAA GAG AAG CCC CTG CCC CTT GGA GTG CCT GAT GCT       1455
Leu Gly Ser Thr Glu Glu Lys Pro Leu Pro Leu Gly Val Pro Asp Ala
                445                 450                 455

GGG ATG AAG CCC AGT TAA CCAGGCCGGT GTGGGCTGTG TCGTAGCCAA              1503
Gly Met Lys Pro Ser
            460

GGTGGGCTGA GCCCTGGCAG GATGACCCTG CGAAGGGGCC CTGGTCCTTC CAGGCCCCCA     1563

CCACTAGGAC TCTGAGGCTC TTTCTGGGCC AAGTTCCTCT AGTGCCCTCC ACAGCCGCAG     1623

CCTCCCTCTG ACCTGCAG                                                  1641
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 462 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
 1               5                  10                  15

Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
            20                  25                  30

Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
        35                  40                  45

Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
    50                  55                  60

Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65                  70                  75                  80

Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
                85                  90                  95

Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
            100                 105                 110

Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
        115                 120                 125

Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
    130                 135                 140

Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145                 150                 155                 160

Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
                165                 170                 175

Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
            180                 185                 190

Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
        195                 200                 205

Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
    210                 215                 220

Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225                 230                 235                 240

Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly
                245                 250                 255

Asp Phe Ala Leu Pro Val Gly Leu Ile Val Gly Val Thr Ala Leu Gly
            260                 265                 270

Leu Leu Ile Ile Gly Val Val Asn Cys Val Ile Met Thr Gln Val Lys
        275                 280                 285

Lys Lys Pro Leu Cys Leu Gln Arg Glu Ala Lys Val Pro His Leu Pro
    290                 295                 300
```

```
Ala Asp Lys Ala Arg Gly Thr Gln Gly Pro Glu Gln Gln His Leu Leu
305                 310                 315                 320

Ile Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser
                325                 330                 335

Ala Leu Asp Arg Arg Ala Pro Thr Arg Asn Gln Pro Gln Ala Pro Gly
            340                 345                 350

Val Glu Ala Ser Gly Ala Gly Glu Ala Arg Ala Ser Thr Gly Ser Ser
        355                 360                 365

Asp Ser Ser Pro Gly Gly His Gly Thr Gln Val Asn Val Thr Cys Ile
    370                 375                 380

Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser Ser Gln
385                 390                 395                 400

Ala Ser Ser Thr Met Gly Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro
                405                 410                 415

Lys Asp Glu Gln Val Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser
            420                 425                 430

Gln Leu Glu Thr Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro
        435                 440                 445

Leu Pro Leu Gly Val Pro Asp Ala Gly Met Lys Pro Ser
    450                 455                 460
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3813 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(vi) ORIGINAL SOURCE:
(A) ORGANISM: mouse
(B) STRAIN: C57BL/6
(G) CELL TYPE: T-helper cell
(H) CELL LINE: 7B9

(vii) IMMEDIATE SOURCE:
(B) CLONE: 11

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 55..1479
(D) OTHER INFORMATION:

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 55..1476
(D) OTHER INFORMATION:

(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: 55..120

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CGCAGCTGAG GCACTAGAGC TCCAGGCACA AGGGCGGGAG CCACCGCTGC CCCT ATG          57
                                                              Met
                                                               1

GCG CCC GCC GCC CTC TGG GTC GCG CTG GTC TTC GAA CTG CAG CTG TGG          105
Ala Pro Ala Ala Leu Trp Val Ala Leu Val Phe Glu Leu Gln Leu Trp
                5                   10                  15

GCC ACC GGG CAC ACA GTG CCC GCC CAG GTT GTC TTG ACA CCC TAC AAA          153
Ala Thr Gly His Thr Val Pro Ala Gln Val Val Leu Thr Pro Tyr Lys
        20                  25                  30

CCG GAA CCT GGG TAC GAG TGC CAG ATC TCA CAG GAA TAC TAT GAC AGG          201
Pro Glu Pro Gly Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp Arg
    35                  40                  45

AAG GCT CAG ATG TGC TGT GCT AAG TGT CCT CCT GGC CAA TAT GTG AAA          249
Lys Ala Gln Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val Lys
50                  55                  60                  65

CAT TTC TGC AAC AAG ACC TCG GAC ACC GTG TGT GCG GAC TGT GAG GCA          297
His Phe Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu Ala
                70                  75                  80

AGC ATG TAT ACC CAG GTC TGG AAC CAG TTT CGT ACA TGT TTG AGC TGC          345
Ser Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser Cys
            85                  90                  95

AGT TCT TCC TGT ACC ACT GAC CAG GTG GAG ATC CGC GCC TGC ACT AAA          393
Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr Lys
        100                 105                 110

CAG CAG AAC CGA GTG TGT GCT TGC GAA GCT GGC AGG TAC TGC GCC TTG          441
Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys Ala Leu
    115                 120                 125

AAA ACC CAT TCT GGC AGC TGT CGA CAG TGC ATG AGG CTG AGC AAG TGC          489
Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu Ser Lys Cys
130                 135                 140                 145

GGC CCT GGC TTC GGA GTG GCC AGT TCA AGA GCC CCA AAT GGA AAT GTG          537
Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro Asn Gly Asn Val
                150                 155                 160

CTA TGC AAG GCC TGT GCC CCA GGG ACG TTC TCT GAC ACC ACA TCA TCC          585
Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser Asp Thr Thr Ser Ser
            165                 170                 175

ACT GAT GTG TGC AGG CCC CAC CGC ATC TGT AGC ATC CTG GCT ATT CCC          633
Thr Asp Val Cys Arg Pro His Arg Ile Cys Ser Ile Leu Ala Ile Pro
        180                 185                 190
```

```
GGA AAT GCA AGC ACA GAT GCA GTC TGT GCG CCC GAG TCC CCA ACT CTA        681
Gly Asn Ala Ser Thr Asp Ala Val Cys Ala Pro Glu Ser Pro Thr Leu
    195                 200                 205

AGT GCC ATC CCA AGG ACA CTC TAC GTA TCT CAG CCA GAG CCC ACA AGA        729
Ser Ala Ile Pro Arg Thr Leu Tyr Val Ser Gln Pro Glu Pro Thr Arg
210                 215                 220                 225

TCC CAA CCC CTG GAT CAA GAG CCA GGG CCC AGC CAA ACT CCA AGC ATC        777
Ser Gln Pro Leu Asp Gln Glu Pro Gly Pro Ser Gln Thr Pro Ser Ile
                230                 235                 240

CTT ACA TCG TTG GGT TCA ACC CCC ATT ATT GAA CAA AGT ACC AAG GGT        825
Leu Thr Ser Leu Gly Ser Thr Pro Ile Ile Glu Gln Ser Thr Lys Gly
            245                 250                 255

GGC ATC TCT CTT CCA ATT GGT CTG ATT GTT GGA GTG ACA TCA CTG GGT        873
Gly Ile Ser Leu Pro Ile Gly Leu Ile Val Gly Val Thr Ser Leu Gly
        260                 265                 270

CTG CTG ATG TTA GGA CTG GTG AAC TGC ATC ATC CTG GTG CAG AGG AAA        921
Leu Leu Met Leu Gly Leu Val Asn Cys Ile Ile Leu Val Gln Arg Lys
    275                 280                 285

AAG AAG CCC TCC TGC CTA CAA AGA GAT GCC AAG GTG CCT CAT GTG CCT        969
Lys Lys Pro Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val Pro
290                 295                 300                 305

GAT GAG AAA TCC CAG GAT GCA GTA GGC CTT GAG CAG CAG CAC CTG TTG       1017
Asp Glu Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu Leu
                310                 315                 320

ACC ACA GCA CCC AGT TCC AGC AGC AGC TCC CTA GAG AGC TCA GCC AGC       1065
Thr Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser
            325                 330                 335

GCT GGG GAC CGA AGG GCG CCC CCT GGG GGC CAT CCC CAA GCA AGA GTC       1113
Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg Val
        340                 345                 350

ATG GCG GAG GCC CAA GGG TTT CAG GAG GCC CGT GCC AGC TCC AGG ATT       1161
Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser Arg Ile
    355                 360                 365

TCA GAT TCT TCC CAC GGA AGC CAC GGG ACC CAC GTC AAC GTC ACC TGC       1209
Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn Val Thr Cys
370                 375                 380                 385

ATC GTG AAC GTC TGT AGC AGC TCT GAC CAC AGT TCT CAG TGC TCT TCC       1257
Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser Ser
                390                 395                 400

CAA GCC AGC GCC ACA GTG GGA GAC CCA GAT GCC AAG CCC TCA GCG TCC       1305
Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala Lys Pro Ser Ala Ser
            405                 410                 415

CCA AAG GAT GAG CAG GTC CCC TTC TCT CAG GAG GAG TGT CCG TCT CAG       1353
Pro Lys Asp Glu Gln Val Pro Phe Ser Gln Glu Glu Cys Pro Ser Gln
        420                 425                 430
```

```
TCC CCG TGT GAG ACT ACA GAG ACA CTG CAG AGC CAT GAG AAG CCC TTG      1401
Ser Pro Cys Glu Thr Thr Glu Thr Leu Gln Ser His Glu Lys Pro Leu
    435                 440                 445

CCC CTT GGT GTG CCG GAT ATG GGC ATG AAG CCC AGC CAA GCT GGC TGG      1449
Pro Leu Gly Val Pro Asp Met Gly Met Lys Pro Ser Gln Ala Gly Trp
450                 455                 460                 465

TTT GAT CAG ATT GCA GTC AAA GTG GCC TGA CCCCTGACAG GGGTAACACC        1499
Phe Asp Gln Ile Ala Val Lys Val Ala  .
                470                 475

CTGCAAAGGG ACCCCCGAGA CCCTGAACCC ATGGAACTTC ATGACTTTTG CTGGATCCAT    1559

TTCCCTTAGT GGCTTCCAGA GCCCCAGTTG CAGGTCAAGT GAGGGCTGAG ACAGCTAGAG    1619

TGGTCAAAAA CTGCCATGGT GTTTTATGGG GGCAGTCCCA GGAAGTTGTT GCTCTTCCAT    1679

GACCCCTCTG GATCTCCTGG GCTCTTGCCT GATTCTTGCT TCTGAGAGGC CCCAGTATTT    1739

TTTCCTTCTA AGGAGCTAAC ATCCTCTTCC ATGAATAGCA CAGCTCTTCA GCCTGAATGC    1799

TGACACTGCA GGGCGGTTCC AGCAAGTAGG AGCAAGTGGT GGCCTGGTAG GGCACAGAGG    1859

CCCTTCAGGT TAGTGCTAAA CTCTTAGGAA GTACCCTCTC CAAGCCCACC GAAATTCTTT    1919

TGATGCAAGA ATCAGAGGCC CCATCAGGCA GAGTTGCTCT GTTATAGGAT GGTAGGGCTG    1979

TAACTCAGTG GTCCAGTGTG CTTTTAGCAT GCCCTGGGTT TGATCCTCAG CAACACATGC    2039

AAAACGTAAG TAGACAGCAG ACAGCAGACA GCACAGCCAG CCCCCTGTGT GGTTTGCAGC    2099

CTCTGCCTTT GACTTTTACT CTGGTGGGCA CACAGAGGGC TGGAGCTCCT CCTCCTGACC    2159

TTCTAATGAG CCCTTCCAAG GCCACGCCTT CCTTCAGGGA ATCTCAGGGA CTGTAGAGTT    2219

CCCAGGCCCC TGCAGCCACC TGTCTCTTCC TACCTCAGCC TGGAGCACTC CCTCTAACTC    2279

CCCAACGGCT TGGTACTGTA CTTGCTGTGA CCCCAACGTG CATTGTCCGG GTTAGGCACT    2339

GTGAGTTGGA ACAGCTCATG ACATCGGTTG AAAGGCCCAC CCGGAAACAG CTAAGCCAGC    2399

TCTTTTGCCA AAGGATTCAT GCCGGTTTTC TAATCAACCT GCTCCCTAGC ATTGCCTGGA    2459

AGGAAAGGGT TCAGGAGACT CCTCAAGAAG CAAGTTCAGT CTCAGGTGCT TGGATGCCAT    2519

GCTCACCGAT TCCACTGGAT ATGAACTTGG CAGAGGAGCC TAGTTGTTGC CATGGAGACT    2579

TAAAGAGCTC AGCACTCTGG AATCAAGATA CTGGACACTT GGGGCCGACT TGTTAAGGCT    2639

CTGCAGCATC AGACTGTAGA GGGGAAGGAA CACGTCTGCC CCCTGGTGGC CCGTCCTGGG    2699

ATGACCTCGG GCCTCCTAGG CAACAAAAGA ATGAATTGGA AAGGATGTTC CTGGGTGTGG    2759

CCTAGCTCCT GTGCTTGTGT GGATCCCTAA AGGGTGTGCT AAGGAGCAAT TGCACTGTGT    2819

GCTGGACAGA ATTCCTGCTT ATAAATGCTT TTTGTTGTTG TTTTGTACAC TGAGCCCTGG    2879

CTGAGCCACC CCACCCCACC TCCCATCCCA CCTTTACACG CCACTCTTGC ATGAGAACCT    2939

GGCTGTCTCC CACTTGTAGC CTGTGGATGC TGAGGAAACA CCCAGCCAAG TAGACTCCAG    2999

GCTTGCCCCT ATCTCCTGCT ATGAGTCTGG CCTCCTCATT GTGTTGTGGG AAGGAGACGG    3059
```

GTTCTGTCAT CTCGGAACGC CCACACCGTG GATGTGAACA ATGGCTGTAC TAGCTTAGAC 3119

CAGCTTAGGG CTCTGCATAT CACAGGAGGG GGAGCAGGGA ACAATTTGAG TGCTGACCTA 3179

TAACACAGTT CCTAAAGGAT CGGGCAGTCC AGAATCTCCT CCTTCAGTGT GTGTGTGTGT 3239

GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT CCATGTTTGC ATGTATGTGT GTGCCAGTGT 3299

GTGGAGGCCC GAGGTTGGCT TTGGGTGTGT TTGATCACTC TCCAGTTACT GAGGCGGGCT 3359

CTCATCTGTA CCCAGAGCTT GCACATTTTC TAGTCTAACT TGATTCAGGG ATCTCTGTCT 3419

GCCTATGGAG GTGCTCAGGT TACAGGCAGG CTGCCATACC TGCCCGACAT TTACATGAAT 3479

ACTAGAGATC TGAATTCTGG TCCTCACACT TGTATACCTG CATTTTATCC ACTAAGACAT 3539

CTCTCCAAGG GCTCCCCCTT CCTATTTAAT AAGTTAGTTT TGAACTGGCA AGATGGCTCA 3599

GTGGGTAAGG CAGTTTGCGG ACAAACCTGA TGACCTGAGT TGGATCCCTG ACCATAAGGT 3659

AGAAGAGACC TGATTCCTGC AAGTTGTCCT CTGACCACCA CCCCATACAT GCTTCTGCAT 3719

ATGTGCACAC ATCACATTCT TGCACACACA CTCACATACC ATAAATGTAA TAAATTTTTT 3779

TAAATAAATT GATTTTATCT TTTAAAAAAA AAAA 3813

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 475 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Ala Pro Ala Ala Leu Trp Val Ala Leu Val Phe Glu Leu Gln Leu
 1               5                  10                  15

Trp Ala Thr Gly His Thr Val Pro Ala Gln Val Val Leu Thr Pro Tyr
            20                  25                  30

Lys Pro Glu Pro Gly Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp
        35                  40                  45

Arg Lys Ala Gln Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val
    50                  55                  60

Lys His Phe Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu
65                  70                  75                  80

Ala Ser Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser
                85                  90                  95

Cys Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr
            100                 105                 110

Lys Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys Ala
        115                 120                 125
```

```
Leu Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu Ser Lys
130                 135                 140

Cys Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro Asn Gly Asn
145                 150                 155                 160

Val Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser Asp Thr Thr Ser
                165                 170                 175

Ser Thr Asp Val Cys Arg Pro His Arg Ile Cys Ser Ile Leu Ala Ile
            180                 185                 190

Pro Gly Asn Ala Ser Thr Asp Ala Val Cys Ala Pro Glu Ser Pro Thr
        195                 200                 205

Leu Ser Ala Ile Pro Arg Thr Leu Tyr Val Ser Gln Pro Glu Pro Thr
    210                 215                 220

Arg Ser Gln Pro Leu Asp Gln Glu Pro Gly Pro Ser Gln Thr Pro Ser
225                 230                 235                 240

Ile Leu Thr Ser Leu Gly Ser Thr Pro Ile Ile Glu Gln Ser Thr Lys
                245                 250                 255

Gly Gly Ile Ser Leu Pro Ile Gly Leu Ile Val Gly Val Thr Ser Leu
            260                 265                 270

Gly Leu Leu Met Leu Gly Leu Val Asn Cys Ile Il  Leu Val Gln Arg
        275                 280                 285

Lys Lys Lys Pro Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val
    290                 295                 300

Pro Asp Glu Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu
305                 310                 315                 320

Leu Thr Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala
                325                 330                 335

Ser Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg
            340                 345                 350

Val Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser Arg
        355                 360                 365

Ile Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn Val Thr
    370                 375                 380

Cys Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser
385                 390                 395                 400

Ser Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala Lys Pro Ser Ala
                405                 410                 415

Ser Pro Lys Asp Glu Gln Val Pro Phe Ser Gln Glu Glu Cys Pro Ser
            420                 425                 430

Gln Ser Pro Cys Glu Thr Thr Glu Thr Leu Gln Ser His Glu Lys Pro
        435                 440                 445

Leu Pro Leu Gly Val Pro Asp Met Gly Met Lys Pro Ser Gln Ala Gly
    450                 455                 460
```

Trp Phe Asp Gln Ile Ala Val Lys Val Ala
465 470 475

Figure 1


HuTNF-R
HuTNF-RΔ235
HuTNF-RΔ185
HuTNF-RΔ163
HuTNF-RΔ142
MuTNF-R

FIGURE 2A

```
                                                GCGAGGCAGGCAGCCTGGAGAGAAGGCG        28

CTGGGCTGCGAGGGCGCGAGGGCGCGAGGGCAGGGGGCAACCGGACCCCGCCCGCATCC                    87

ATG GCG CCC GTC GCC GTC TGG GCC GCG CTG GCC GTC GGA CTG GAG                     132
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu                     -8

CTC TGG GCT GCG GCG CAC GCC TTG CCC GCC CAG GTG GCA TTT ACA                     177
Leu Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr                      8

CCC TAC GCC CCG GAG CCC GGG AGC ACA TGC CGG CTC AGA GAA TAC                     222
Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr                      23

TAT GAC CAG ACA GCT CAG ATG TGC TGC AGC AAA TGC TCG CCG GGC                     267
Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly                      38

CAA CAT GCA AAA GTC TTC TGT ACC AAG ACC TCG GAC ACC GTG TGT                     312
Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys                      53

GAC TCC TGT GAG GAC AGC ACA TAC ACC CAG CTC TGG AAC TGG GTT                     357
Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val                      68

CCC GAG TGC TTG AGC TGT GGC TCC CGC TGT AGC TCT GAC CAG GTG                     402
Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val                      83

GAA ACT CAA GCC TGC ACT CGG GAA CAG AAC CGC ATC TGC ACC TGC                     447
Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys                      98

AGG CCC GGC TGG TAC TGC GCG CTG AGC AAG CAG GAG GGG TGC CGG                     492
Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg                     113

CTG TGC GCG CCG CTG CGC AAG TGC CGC CCG GGC TTC GGC GTG GCC                     537
Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala                     128

AGA CCA GGA ACT GAA ACA TCA GAC GTG GTG TGC AAG CCC TGT GCC                     582
Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala                     143

CCG GGG ACG TTC TCC AAC ACG ACT TCA TCC ACG GAT ATT TGC AGG                     627
Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg                     158

CCC CAC CAG ATC TGT AAC GTG GTG GCC ATC CCT GGG AAT GCA AGC                     672
Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser                     173

ATG GAT GCA GTC TGC ACG TCC ACG TCC CCC ACC CGG AGT ATG GCC                     717
Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser Met Ala                     188

CCA GGG GCA GTA CAC TTA CCC CAG CCA GTG TCC ACA CGA TCC CAA                     762
Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser Gln                     203

CAC ACG CAG CCA ACT CCA GAA CCC AGC ACT GCT CCA AGC ACC TCC                     807
His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser                     218

TTC CTG CTC CCA ATG GGC CCC AGC CCC CCA GCT GAA GGG AGC ACT                     852
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr                     233

GGC GAC TTC GCT CTT CCA GTT GGA CTG ATT GTG GGT GTG ACA GCC                     897
Gly Asp Phe Ala Leu Pro Val Gly Leu Ile Val Gly Val Thr Ala                     248
```

Figure 2B

```
TTG GGT CTA CTA ATA ATA GGA GTG GTG AAC TGT GTC ATC ATG ACC      942
Leu Gly Leu Leu Ile Ile Gly Val Val Asn Cys Val Ile Met Thr      263

CAG GTG AAA AAG AAG CCC TTG TGC CTG CAG AGA GAA GCC AAG GTG      987
Gln Val Lys Lys Lys Pro Leu Cys Leu Gln Arg Glu Ala Lys Val      278

CCT CAC TTG CCT GCC GAT AAG GCC CGG GGT ACA CAG GGC CCC GAG     1032
Pro His Leu Pro Ala Asp Lys Ala Arg Gly Thr Gln Gly Pro Glu      293

CAG CAG CAC CTG CTG ATC ACA GCG CCG AGC TCC AGC AGC AGC TCC     1077
Gln Gln His Leu Leu Ile Thr Ala Pro Ser Ser Ser Ser Ser Ser      308

CTG GAG AGC TCG GCC AGT GCG TTG GAC AGA AGG GCG CCC ACT CGG     1122
Leu Glu Ser Ser Ala Ser Ala Leu Asp Arg Arg Ala Pro Thr Arg      323

AAC CAG CCA CAG GCA CCA GGC GTG GAG GCC AGT GGG GCC GGG GAG     1167
Asn Gln Pro Gln Ala Pro Gly Val Glu Ala Ser Gly Ala Gly Glu      338

GCC CGG GCC AGC ACC GGG AGC TCA GAT TCT TCC CCT GGT GGC CAT     1212
Ala Arg Ala Ser Thr Gly Ser Ser Asp Ser Ser Pro Gly Gly His      353

GGG ACC CAG GTC AAT GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC     1257
Gly Thr Gln Val Asn Val Thr Cys Ile Val Asn Val Cys Ser Ser      368

TCT GAC CAC AGC TCA CAG TGC TCC TCC CAA GCC AGC TCC ACA ATG     1302
Ser Asp His Ser Ser Gln Cys Ser Ser Gln Ala Ser Ser Thr Met      383

GGA GAC ACA GAT TCC AGC CCC TCG GAG TCC CCG AAG GAC GAG CAG     1347
Gly Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro Lys Asp Glu Gln      398

GTC CCC TTC TCC AAG GAG GAA TGT GCC TTT CGG TCA CAG CTG GAG     1392
Val Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser Gln Leu Glu      413

ACG CCA GAG ACC CTG CTG GGG AGC ACC GAA GAG AAG CCC CTG CCC     1437
Thr Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro Leu Pro      428

CTT GGA GTG CCT GAT GCT GGG ATG AAG CCC AGT                     1470
Leu Gly Val Pro Asp Ala Gly Met Lys Pro Ser                      439

TAACCAGGCCGGTGTGGGCTGTGTCGTAGCCAAGGTGGGCTGAGCCCTGGCAGGATGAC

CCTGCGAAGGGGCCCTGGTCCTTCCAGGCCCCCACCACTAGGACTCTGAGGCTCTTTCT

GGGCCAAGTTCCTCTAGTGCCCTCCACAGCCGCAGCCTCCCTCTGACCTGCAG...
```

-275

Figure 2A

```
                                                    CGCAGCTGAGGCACTAGAGCTCC      23

AGGCACAAGGGCGGGAGCCACCGCTGCCCCT ATG GCG CCC GCC GCC CTC TGG      75
                                 Met Ala Pro Ala Ala Leu Trp     -16

GTC GCG CTG GTC TTC GAA CTG CAG CTG TGG GCC ACC GGG CAC ACA      120
Val Ala Leu Val Phe Glu Leu Gln Leu Trp Ala Thr Gly His Thr      -1

GTG CCC GCC CAG GTT GTC TTG ACA CCC TAC AAA CCG GAA CCT GGG      165
Val Pro Ala Gln Val Val Leu Thr Pro Tyr Lys Pro Glu Pro Gly      15

TAC GAG TGC CAG ATC TCA CAG GAA TAC TAT GAC AGG AAG GCT CAG      210
Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp Arg Lys Ala Gln      30

ATG TGC TGT GCT AAG TGT CCT CCT GGC CAA TAT GTG AAA CAT TTC      255
Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val Lys His Phe      45

TGC AAC AAG ACC TCG GAC ACC GTG TGT GCG GAC TGT GAG GCA AGC      300
Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu Ala Ser      60

ATG TAT ACC CAG GTC TGG AAC CAG TTT CGT ACA TGT TTG AGC TGC      345
Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser Cys      75

AGT TCT TCC TGT ACC ACT GAC CAG GTG GAG ATC CGC GCC TGC ACT      390
Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr      90

AAA CAG CAG AAC CGA GTG TGT GCT TGC GAA GCT GGC AGG TAC TgC      435
Lys Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys     105

GCC TTG AAA ACC CAT TCT GGC AGC TGT CGA CAG TGC ATG AGG CTG      480
Ala Leu Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu     120

AGC AAG TGC GGC CCT GGC TTC GGA GTG GCC AGT TCA AGA GCC CCA      525
Ser Lys Cys Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro     135

AAT GGA AAT GTG CTA TGC AAG GCC TGT GCC CCA GGG ACG TTC TCT      570
Asn Gly Asn Val Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser     150

GAC ACC ACA TCA TCC ACT GAT GTG TGC AGG CCC CAC CGC ATC TGT      615
Asp Thr Thr Ser Ser Thr Asp Val Cys Arg Pro His Arg Ile Cys     165

AGC ATC CTG GCT ATT CCC GGA AAT GCA AGC ACA GAT GCA GTC TGT      660
Ser Ile Leu Ala Ile Pro Gly Asn Ala Ser Thr Asp Ala Val Cys     180

GCG CCC GAG TCC CCA ACT CTA AGT GCC ATC CCA AGG ACA CTC TAC      705
Ala Pro Glu Ser Pro Thr Leu Ser Ala Ile Pro Arg Thr Leu Tyr     195

GTA TCT CAG CCA GAG CCC ACA AGA TCC CAA CCC CTG GAT CAA GAG      750
Val Ser Gln Pro Glu Pro Thr Arg Ser Gln Pro Leu Asp Gln Glu     210

CCA GGG CCC AGC CAA ACT CCA AGC ATC CTT ACA TCG TTG GGT TCA      795
Pro Gly Pro Ser Gln Thr Pro Ser Ile Leu Thr Ser Leu Gly Ser     225

ACC CCC ATT ATT GAA CAA AGT ACC AAG GGT GGC ATC TCT CTT CCA      840
Thr Pro Ile Ile Glu Gln Ser Thr Lys Gly Gly Ile Ser Leu Pro     240

ATT GGT CTG ATT GTT GGA GTG ACA TCA CTG GGT CTG CTG ATG TTA      885
Ile Gly Leu Ile Val Gly Val Thr Ser Leu Gly Leu Leu Met Leu     255
```

Figure 3B

```
GGA CTG GTG AAC TGC ATC ATC CTG GTG CAG AGG AAA AAG AAG CCC    930
Gly Leu Val Asn Cys Ile Ile Leu Val Gln Arg Lys Lys Lys Pro    270

TCC TGC CTA CAA AGA GAT GCC AAG GTG CCT CAT GTG CCT GAT GAG    975
Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val Pro Asp Glu    285

AAA TCC CAG GAT GCA GTA GGC CTT GAG CAG CAG CAC CTG TTG ACC   1020
Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu Leu Thr    300

ACA GCA CCC AGT TCC AGC AGC AGC TCC CTA GAG AGC TCA GCC AGC   1065
Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser    315

GCT GGG GAC CGA AGG GCG CCC CCT GGG GGC CAT CCC CAA GCA AGA   1110
Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg    330

GTC ATG GCG GAG GCC CAA GGG TTT CAG GAG GCC CGT GCC AGC TCC   1155
Val Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser    345

AGG ATT TCA GAT TCT TCC CAC GGA AGC CAC GGG ACC CAC GTC AAC   1200
Arg Ile Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn    360

GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC TCT GAC CAC AGT TCT   1245
Val Thr Cys Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser    375

CAG TGC TCT TCC CAA GCC AGC GCC ACA GTG GGA GAC CCA GAT GCC   1290
Gln Cys Ser Ser Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala    390

AAG CCC TCA GCG TCC CCA AAG GAT GAG CAG GTC CCC TTC TCT CAG   1335
Lys Pro Ser Ala Ser Pro Lys Asp Glu Gln Val Pro Phe Ser Gln    405

GAG GAG TGT CCG TCT CAG TCC CCG TGT GAG ACT ACA GAG ACA CTG   1380
Glu Glu Cys Pro Ser Gln Ser Pro Cys Glu Thr Thr Glu Thr Leu    420

CAG AGC CAT GAG AAG CCC TTG CCC CTT GGT GTG CCG GAT ATG GGC   1425
Gln Ser His Glu Lys Pro Leu Pro Leu Gly Val Pro Asp Met Gly    435

ATG AAG CCC AGC CAA GCT GGC TGG TTT GAT CAG ATT GCA GTC AAA   1470
Met Lys Pro Ser Gln Ala Gly Trp Phe Asp Gln Ile Ala Val Lys    450

GTG GCC                                                      1476
Val Ala                                                       452


TGACCCCTGACAGGGGTAACACCCTGCAAAGGGACCCCCGAGACCCTGAACCCATGGAAC  1536
TTCATGACTTTTGCTGGATCCATTTCCCTTAGTGGCTTCCAGAGCCCCAGTTGCAGGTCA  1596
AGTGAGGGCTGAGACAGCTAGAGTGGTCAAAAACTGCCATGGTGTTTTATGGGGGCAGTC  1656
CCAGGAAGTTGTTGCTCTTCCATGACCCCTCTGGATCTCCTGGGCTCTTGCCTGATTCTT  1716
GCTTCTGAGAGGCCCCAGTATTTTTTCCTTCTAAGGAGCTAACATCCTCTTCCATGAATA  1776
GCACAGCTCTTCAGCCTGAATGCTGACACTGCAGGGCGGTTCCAGCAAGTAGGAGCAAGT  1836
GGTGGCCTGGTAGGGCACAGAGGCCCTTCAGGTTAGTGCTAAACTCTTAGGAAGTACCCT  1896
CTCCAAGCCCACCGAAATTCTTTTGATGCAAGAATCAGAGGCCCCATCAGGCAGAGTTGC  1956
TCTGTTATAGGATGGTAGGGCTGTAACTCAgTGGTCCAgTGTGCTTTTAGCATGCCCTGG  2016
GTTTGATCCTCAGCAACACATGCAAAACGTAAGTAGACAGCAGACAGCAGACAGCACAGC  2076
CAGCCCCCTGTGTGGTTTGCAGCCTCTGCCTTTGACTTTTACTCTGGTGGGCACACAGAG  2136
GGCTGGAGCTCCTCCTCCTGACCTTCTAATGAGCCCTTCCAAGGCCACGCCTTCCTTCAG  2196
GGAATCTCAGGGACTGTAGAGTTCCCAGGCCCCTGCAGCCACCTGTCTCTTCCTACCTCA  2256
GCCTGGAGCAcTCCCTCTAACTCCCCAACGgCTTGGTACTGTACTTGCTGTGACCCCAAC  2316
GTGCATTGTCCGGGTTAGGCACTGTGAGTTGGAACAGCTcATGACATCGGTTGAAAGGCC  2376
CACCCGGAAACAGCTAAGCCAGCTCTTTTGCCAAAGGATTCATGCCGGTTTTCTAATCAa  2436
CCTGCTCCCTAGCATTGCCTGGAAGGAAAGGGTTCAGGAGACTCCTCAAGAAGCAAGTTC  2496
AGTCTCAGGTGCTTGGATGCCATGCTCACCGATTCCACTGGATATGAACTTGGCAGAGGA  2556
```

Figure 3C

```
GCCTAGTTGTTGCCATGGAGACTTAAAGAGCTCAGCACTCTGGAATCAAGATACTGGACA  2616
CTTGGGGCCGACTTGTTAAGGCTCTGCAGCATCAGACTGTAGAGGGGAAGGAACACGTCT  2676
GCCCCCTGGTGGCCCGTCCTGGGATGACCTCGGGCCtCCTAGGCAACAAAAGAATGAATT  2736
GGAAAGGATGTTCCTGGGTGTGGCCTAGCTCCTGTGCTTGTGTGGATCCCTAAAGGGTGT  2796
GCTAAGGAGCAATTGCACTGTGTGCTGGACAGAATTCCTGCTTATAAATGCTTTTTGTTG  2856
TTGTTTTGTACACTGAGCCCTGGCTGAGCCACCCCACCCCACCTCCCATCCCACCTTTAC  2916
ACGCCACTCTTGCATGAGAACCTGGCTGTCTCCCACTTGTAGCCTGTGGATGCTGAGGAA  2976
ACACCCAGCCAAGTAGACTCCAGGCTTgCCCCTATCTCCTGcTaTGAGTcTggCCTCCTC  3036
AtTgTGTTGTGGGAAgGAGACGGGtTCTGTCATCTCGGAAcgCCCACACCGTGGATGTGA  3096
ACAaTGGCTGTACTAGCTTAGACCAgCTTAGGGCTCTGCATATCACAGGAGGGGGAGCAG  3156
GGAACAATTTGAGTGCTGACCTATAACACAgTTCCTAAAGGATCGGGCAGTCCAGAATCT  3216
CCTCCTTCAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCCATGTT  3276
TGCATGTATGTGTGTGCCAGTGTGTGGAGGCCCGAGGTTGGCTTTGGGTGTGTTTGATCA  3336
CTCTCCAGTTACTGAGGCGGGCTCTCATCTGTACCCAGAGCTTGCACATTTTCTAGTCTA  3396
ACTTGATTCAGGGATCTCTGTCTGCCTATGGAGgTGCTCAGGTTACAGGCAGGCTGCCAT  3456
ACCTGCCCGACATTTACATGAATACTAGAGATCTGAATTCTGGTCCTCACACTTGTATAC  3516
CTGCATTTTATCCACTAAGACATCTCTCCAAGGGCTCCCCCTTCCTATTTAATAAGTTAG  3576
TTTTGAACTGGCAAGATGGCTCAGTGGGTAAGGCAGTTTGCGGACAAACCTGATGACCTG  3636
AGTTGGATCCCTGACCATAAGGTAGAAGAGACCTGATTCCTGCAAGTTGTCCTCTGACCA  3696
CCACCCCATACATGCTTCTGCATATGTGCACACATCACATTCTTGCACACACACTCACAT  3756
ACCATAAATGTAATAAATTTTTTTTAAATAAATTGATTTTATCTTTTAAAAAAAAAAA    3813
```

European Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 9875

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
P,X	SCIENCE, vol. 248, May 1990, pages 1019-1023, Washington, US; C.A. SMITH et al.: "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins" * Whole article *	1-10	C 12 N 15/12 C 12 P 21/02 A 61 K 37/02 C 12 P 21/08 G 01 N 33/68
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 87, August 1990, pages 6151-6155, Washington, DC, US; K.A. HELLER et al.: "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor" * Whole article *	1-8,11	
P,X,D	CELL, vol. 61, April 1990, pages 351-359, Cambridge, Mass., US; H. LOETSCHER et al.: "Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor" * Whole article *	1,2,9,10, 11	
P,X,D	CELL, vol. 61, April 1990, pages 361-370, Cambridge, Mass., US; T.J. SCHALL et al.: "Molecular cloning and expression of a receptor for human tumor necrosis factor" * Whole article *	1,2,9-11	TECHNICAL FIELDS SEARCHED (Int. Cl.5) C 12 N
P,X,D	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 3, January 1990, pages 1531-1536, Baltimore, US; H. ENGELMANN et al.: "Two tumor necrosis factor-binding proteins purified from human urine" * Whole article *	11,12,20	
P,X,D	GB-A-2 218 101 (GLAXO GROUP LTD) * Claims *	1-3,9-12, 16,18	

The present search report has been drawn up for all claims

Place of search	Date of completion of search	Examiner
The Hague	28 November 90	HUBER A.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document
T : theory or principle underlying the invention

E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

European Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 9875

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
P,X	EP-A-0 334 165 (HOFFMANN-LA ROCHE) * Claims; page 4, example 1 *	11,20	
X	EP-A-0 308 378 (YEDA RESEARCH AND DEVELOPMENT CO.) * Claims *	1-3,9-12, 16,18,20	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)

The present search report has been drawn up for all claims

Place of search	Date of completion of search	Examiner
The Hague	28 November 90	HUBER A.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same catagory
A : technological background
O : non-written disclosure
P : intermediate document
T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons
& : member of the same patent family, corresponding document

VOLLMACHT[1] / AUTHORISATION[1] / POUVOIR[1]

Bitte vor dem Ausfüllen des Formblatts Rückseite beachten
Please read the notes overleaf before completing the form
Veuillez lire les remarques au verso avant de remplir le formulaire

Nr. der Anmeldung (des Patents)/Application/Patent No./
N° de la demande (du brevet)

0422339

Zeichen des Vertreters (der Vertreter) (max. 15 Positionen)
Representative's Reference (max. 15 spaces)
Référence du (des) mandataire(s) (15 caractères ou espaces au maximum)

JRH/I1540/00015

Ich (Wir) / I (We) / Je (Nous)[2]

IMMUNEX CORPORATION
51 UNIVERSITY STREET
WASHINGTON 98101
UNITED STATES OF AMERICA

bevollmächtige(n) hiermit / do hereby authorise / autorise (autorisons) par le présente[3]

HORNBY John Richard, a legal practitioner qualified in the United Kingdom of Clifford Chance, 200 Aldersgate Street, London, EC1A 4JJ, UNITED KINGDOM

☐ (Weitere Vertreter sind auf einem gesonderten Blatt angegeben. / Additional representatives indicated on supplementary sheet. / Les autres mandataires sont mentionnés sur une feuille supplémentaire.)

mich (uns) zu vertreten als / to represent me (us) as / à me (nous) représenter en tant que

☐ Anmelder oder Patentinhaber / applicant(s) or patent proprietor(s) / demandeur(s) ou titulaire(s) du brevet,

☒ Einsprechenden (Einsprechende) / opponent(s) / opposant(s),

für mich (uns) zu handeln in den durch das Europäische Patentübereinkommen geschaffenen Verfahren in der (den) folgenden europäischen Patentanmeldung(en) oder dem (den) folgenden europäischen Patent(en)[4] und Zahlungen für mich (uns) in Empfang zu nehmen:
to act for me (us) in all proceedings established by the European Patent Convention concerning the following European patent application(s) or patent(s)[4] and to receive payments on my (our) behalf:
à agir en mon (notre) nom dans toute procédure instituée par la Convention sur le brevet européen et concernant la (les) demande(s) de brevet ou le (les) brevet(s) européen(s)[4] suivant(s) et à recevoir des paiements en mon (notre) nom:

European Patent No. 0422339 entitled "Tumor necrosis factor (TNF) inhibitor and method for obtaining the same."

☐ Weitere Anmeldungen oder Patente sind auf einem gesonderten Blatt angegeben. / Additional applications or patents indicated on supplementary sheet. / Les autres demandes ou brevets sont mentionnés sur une feuille supplémentaire.

☐ Die Vollmacht gilt auch für Verfahren nach dem Vertrag über die internationale Zusammenarbeit auf dem Gebiet des Patentwesens.
This authorisation shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.
Ce pouvoir s'applique également à toute procédure instituée par le Traité de coopération en matière de brevets.

☒ Diese Vollmacht gilt auch für eventuelle europäische Teilanmeldungen./This authorisation also covers any European divisional applications. / Le présent pouvoir vaut également pour les demandes divisionnaires européennes qui pourraient être déposées.

☒ Untervollmacht kann erteilt werden. / Sub-authorisation may be given. / Le pouvoir pourra être délégué.

☐ Ich (Wir) widerrufe(n) hiermit frühere Vollmachten in Sachen der obenbezeichneten Anmeldung(en) oder des obenbezeichneten Patents (der obenbezeichneten Patente)[4]. / I (We) hereby revoke previous authorisations in respect of the above application(s) or patent(s)[4]./ Je révoque (Nous révoquons) par la présente tout pouvoir antérieur, donné pour la (les) demande(s) ou le (les) brevet(s) mentionné(s) ci-dessus[4].

Ort / Place / Lieu Seattle, Washington USA

Datum / Date August 11, 1998

Unterschrift(en) / Signature(s)[5]

For Immunex Corporation
Scott G. Hallquist
Sr. Vice President, General Counsel

Das Formblatt muß vom (von den) Vollmachtgeber(n) (bei juristischen Personen vom Unterschriftsberechtigten) eigenhändig unterzeichnet sein. Nach der Unterschrift bitte den (die) Namen des (der) Unterzeichneten mit Schreibmaschine wiederholen (bei juristischen Personen die Stellung des Unterschriftsberechtigten innerhalb der Gesellschaft angeben).

The form must bear the personal signature(s) of the authorisor(s) (in the case of legal persons, that of the officer empowered to sign). After the signature, please type the name(s) of the signatory(ies) adding, in the case of legal persons, his (their) position within the company.

Le formulaire doit être signé de la propre main du (des) mandant(s) (dans le cas de personnes morales, de la personne ayant qualité pour signer). Veuillez ajouter à la machine, après la signature, le (les) nom(s) du (des) signataire(s) en mentionnant, dans le cas de personnes morales, ses (leurs) fonctions au sein de la société.

VOLLMACHT[1] / AUTHORISATION[1] / POUVOIR[1]

Bitte vor dem Ausfüllen des Formblatts Rückseite beachten
Please read the notes overleaf before completing the form
Veuillez lire les remarques au verso avant de remplir le formulaire

Zeichen des Vertreters (der Vertreter) (max. 15 Positionen)
Representative's Reference (max. 15 spaces)
Référence du (des) mandataire(s) (15 caractères ou espaces au maximum)
JRH/I1540/00015

Nr. der Anmeldung (des Patents)/Application/Patent No./
N° de la demande (du brevet)
0422339

Ich (Wir) / I (We) / Je (Nous)[2]

IMMUNEX CORPORATION
51 UNIVERSITY STREET
WASHINGTON 98101
UNITED STATES OF AMERICA

bevollmächtige(n) hiermit / do hereby authorise / autorise (autorisons) par le présente[3]

HORNBY John Richard, a legal practitioner qualified in the United Kingdom of Clifford Chance, 200 Aldersgate Street, London, EC1A 4JJ, UNITED KINGDOM

☐ (Weitere Vertreter sind auf einem gesonderten Blatt angegeben. / Additional representatives indicated on supplementary sheet. / Les autres mandataires sont mentionnés sur une feuille supplémentaire.)

mich (uns) zu vertreten als / to represent me (us) as / à me (nous) représenter en tant que

☐ Anmelder oder Patentinhaber / applicant(s) or patent proprietor(s) / demandeur(s) ou titulaire(s) du brevet,

☒ Einsprechenden (Einsprechende) / opponent(s) / opposant(s),

für mich (uns) zu handeln in den durch das Europäische Patentübereinkommen geschaffenen Verfahren in der (den) folgenden europäischen Patentanmeldung(en) oder dem (den) folgenden europäischen Patent(en)[4] und Zahlungen für mich (uns) in Empfang zu nehmen:
to act for me (us) in all proceedings established by the European Patent Convention concerning the following European patent application(s) or patent(s)[4] and to receive payments on my (our) behalf:
à agir en mon (notre) nom dans toute procédure instituée par la Convention sur le brevet européen et concernant la (les) demande(s) de brevet ou le (les) brevet(s) européen(s)[4] suivant(s) et à recevoir des paiements en mon (notre) nom:

European Patent No. 0422339 entitled "Tumor necrosis factor (TNF) inhibitor and method for obtaining the same."

☐ Weitere Anmeldungen oder Patente sind auf einem gesonderten Blatt angegeben. / Additional applications or patents indicated on supplementary sheet. / Les autres demandes ou brevets sont mentionnés sur une feuille supplémentaire.

☐ Die Vollmacht gilt auch für Verfahren nach dem Vertrag über die internationale Zusammenarbeit auf dem Gebiet des Patentwesens.
This authorisation shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.
Ce pouvoir s'applique également à toute procédure instituée par le Traité de coopération en matière de brevets.

☒ Diese Vollmacht gilt auch für eventuelle europäische Teilanmeldungen./This authorisation also covers any European divisional applications. / Le présent pouvoir vaut également pour les demandes divisionnaires européennes qui pourraient être déposées.

☒ Untervollmacht kann erteilt werden. / Sub-authorisation may be given. / Le pouvoir pourra être délégué.

☐ Ich (Wir) widerrufe(n) hiermit frühere Vollmachten in Sachen der obenbezeichneten Anmeldung(en) oder des obenbezeichneten Patents (der obenbezeichneten Patente)[4]. / I (We) hereby revoke previous authorisations in respect of the above application(s) or patent(s)[4]./ Je révoque (Nous révoquons) par la présente tout pouvoir antérieur, donné pour la (les) demande(s) ou le (les) brevet(s) mentionné(s) ci-dessus[4].

Ort / Place / Lieu Seattle, Washington USA

Datum / Date August 11, 1998

Unterschrift(en) / Signature(s)[5]

For Immunex Corporation
Scott G. Hallquist
Sr Vice President, General Counsel

Das Formblatt muß vom (von den) Vollmachtgeber(n) (bei juristischen Personen vom Unterschriftsberechtigten) eigenhändig unterzeichnet sein. Nach der Unterschrift bitte den (die) Namen des (der) Unterzeichneten mit Schreibmaschine wiederholen (bei juristischen Personen die Stellung des Unterschriftsberechtigten innerhalb der Gesellschaft angeben).

The form must bear the personal signature(s) of the authorisor(s) (in the case of legal persons, that of the officer empowered to sign). After the signature, please type the name(s) of the signatory(ies) adding, in the case of legal persons, his (their) position within the company.

Le formulaire doit être signé de la propre main du (des) mandant(s) (dans le cas de personnes morales, de la personne ayant qualité pour signer). Veuillez ajouter à la machine, après la signature, le (les) nom(s) du (des) signataire(s) en mentionnant, dans le cas de personnes morales, ses (leurs) fonctions au sein de la société.

Payment of fees and costs

European Patent Office
Directorate
Cash and Accounts
D – 80298 München

Please complete using a typewriter or a word processor

Name of payer
CLIFFORD CHANCE

Payer's reference
JRH/11540/15

Address
200 ALDERSGATE STREET
LONDON EC1A 4JJ
UNITED KINGDOM

Mode of payment
- [X] Bank/Giro transfer ① — Bank/Giro Office: BARCLAYS BANK, LONDON
- [ ] Enclosed Cheque No.
- [ ] Debit from deposit account with the EPO is requested ② — Deposit account No.

Purpose of payment — Patent application / Patent No. (A separate form is required for each application)

EP 422339 PCT –

Explanations:	Code		Currency ③	Amount
① Payment must be made without charge to the payee. For European Patent Organisation accounts and corresponding currencies of payment see overleaf.	001	Filing fee		
	002	Search fee		
	005	Designation fee(s) ④		
	015	Claims fee(s) (Rule 31 (1) EPC)		
② Debits from deposit accounts with the European Patent Office may only be made in DEM.	055	Additional copy		
	006	Examination fee		
	007	Fee for grant including fee for printing (up to 35 pages)		
③ Payments must be made in the currency of the State in which the EPO account in question is held. Please use the abbreviations for currencies of payment shown overleaf.	008	Additional fee for printing (more than 35 pages)		
	033	Renewal fee for the 3rd year		
	034	Renewal fee for the 4th year		
	035	Renewal fee for the 5th year		
④ Contracting States should only be specified if they differ from those designated in box 33 of EPO Form 1001 (Request for Grant) or in box V of PCT Form RO/101.		Extension fee(s) for ⑤ :		
	010	Opposition Fee	GB	411.00
⑤ When extension fees are paid, the States for which they are intended must be specified.				
		Total		

Signature [JOHN HORNBY, CLIFFORD CHANCE, LEGAL REPRESENTATIVE]

Place, Date 26/10/1998 LONDON, ENGLAND

TT/CHAPS PAYMENT REQUEST

TO: CASHIERS(UGS5)

FROM: John R. Hornby DATE: 18.6.98

FILE NO: I1540/15

CLIENT: Immunex Corporation

MATTER: Amgen Inc.

PURPOSE OF PAYMENT: Notice of Opposition to European Patent

Please arrange to TT/CHAPS the sum of £ 411 00

SUM NOT TO EXCEED (in words) Four hundred and eleven pounds

to the undermentioned account to arrive by ..... hrs on .....

BANK: Barclays Bank plc

ADDRESS: 54 Lombard Street
Po. Box 544
London EC3V 9EX

SORT CODE: 20-00-00

ACCOUNT NAME: European Patent Office

ACCOUNT NO: 60271489

CASHIERS ONLY 90284866 Bank Code Z/ BF008		
	Time	Initial
Input	12.55	
Verify		
Authorise	13.32	
Release		

SIGNED .....

AUTHORISATION (2 Departmental Partners required)

SIGNED John Hornby Initials (JRH)

SIGNED ..... Initials ( )

CHECKED BY ..... Cashier

FPO 39 (1/95)

Europäisches Patentamt | European Patent office | Office européen des brevets

Einsender / Sender / Expéditeur :

D-80298 München
(+49-89) 2399-0
Tx 523 656 epmu d
Fax (+49-89) 23 99-44 65

P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
(+31-70) 340-2040
Tx 31 651 epo nl
Fax (+31-70) 340-3016

D-10958 Berlin
(+49-30) 25901-0
Fax (+49-30) 25901-840

Bestätigung über den Eingang nachgereichter Untedagen für Patentanmeldungen/Patente beim Europäischen Patentamt

Datum und Ort des Eingangs sind aus der Perforation dieser Eingangsbestätigung ersichtlich (M + Datum = Einreichungsort München; Datum ohne Zusatz = Einreichungsort Den Haag; Datum + B = Einreichungsort Berlin)

Acknowledgement of receipt for subsequently filed items relating to patent applications/patents at the European Patent Office

Date and place of receipt are shown by the perforation appearing on this receipt

(M + date = Munich as place of receipt; date alone = The Hague as place of receipt; date + B = Berlin as place of receipt)

Accusé de réception à l'Office européen des brevets de pièces produites postérieurement au dépôt d'une demande de brevet/ à la délivrance d'un brevet européen

La date et le lieu de réception sont indiqués par la perforation du présent accusé de réception (M + date = pièces reçues à Munich; date seule = pièces reçues à La Haye; date + B = pièces reçues à Berlin)

Eingereichte Unterlagen Anmeldungs- (und Direktions-*) Nr./Patent Nr. Application (and Directorate*) No./Patent No. N de la demande (et de la direction*)/n du brevet 0,422,389	Items filed Ihr Zeichen Your reference JRH/I1540/15 Votre référence	Pièces envoyées ggfs. Art und Datum der Unterlagen** Nature and date of items (optional)** Nature et date des pièces (facultatif)**
1	Original Notice of Opposition on form 2300.1 dated 26 October 1998.	
2	Statement of Facts and Arguments.	
3	Copies of the publications referred to in 1 above.	
4	2 sets of copies of documents at 1-3 (inclusive) above.	
5	Original Authorisation on form 1003 dated 11 August 1998.	
6	Copy Authorisation.	
7	Original Form 1010 dated 26 October 1998	
8		
9		
10		

* falls bereits bekannt

** Der Eingang der angegebenen Unterlagen wird bestätigt. Enthält diese Spalte keine Eintragungen, so wird lediglich bestätigt, daß eine Sendung zu dem angegebenen Aktenzeichen eingegangen ist.

* if already known

** The receipt of the items indicated is confirmed. If this column does not contain any entries, it is only confirmed that an item has been received for the indicated file.

* si déjà connu

** La réception des pièces indiquées est confirmée. Faute de mention dans cette colonne, le présent accusé de réception se rapporte à une pièce quelconque envoyée sous la référence indiquée.

EPA/EPO/OEB Form 1037.1 09.95
Eingangsbestätigung für Einsender
Acknowledgement of receipt for sender
Accusé de réception expéditeur

Europäisches Patentamt | European Patent office | Office européen des brevets

Einsender / Sender / Expéditeur :

D-80298 München
(+49-89) 2399-0
Tx 523 656 epmu d
Fax (+49-89) 23 99-44 65

P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
(+31-70) 340-2040
Tx 31 651 epo nl
Fax (+31-70) 340-3016

D-10958 Berlin
(+49-30) 25901-0
Fax (+49-30) 25901-840

Bestätigung über den Eingang nachgereichter Untedagen für Patentanmeldungen/Patente beim Europäischen Patentamt

Datum und Ort des Eingangs sind aus der Perforation dieser Eingangsbestätigung ersichtlich (M + Datum = Einreichungsort München; Datum ohne Zusatz = Einreichungsort Den Haag; Datum + B = Einreichungsort Berlin)

Acknowledgement of receipt for subsequently filed items relating to patent applications/patents at the European Patent Office

Date and place of receipt are shown by the perforation appearing on this receipt

(M + date = Munich as place of receipt; date alone = The Hague as place of receipt; date + B = Berlin as place of receipt)

Accusé de réception à l'Office européen des brevets de pièces produites postérieurement au dépôt d'une demande de brevet/ à la délivrance d'un brevet européen

La date et le lieu de réception sont indiqués par la perforation du présent accusé de réception
(M + date = pièces reçues à Munich; date seule = pièces reçues à La Haye; date + B = pièces reçues à Berlin)

Eingereichte Unterlagen / Items filed / Pièces envoyées		
Anmeldungs- (und Direktions-*) Nr./Patent Nr. Application (and Directorate*) No./Patent No. N de la demande (et de la direction*)/n du brevet 0,422,339	Ihr Zeichen / Your reference / Votre référence JRH/I1540/15	ggfs. Art und Datum der Unterlagen** Nature and date of items (optional)** Nature et date des pièces (facultatif)**
1	Original Notice of Opposition on form 2300.1 dated 26 October 1998.	
2	Statement of Facts and Arguments.	
3	Copies of the publications referred to in 1 above.	
4	2 sets of copies of documents at 1-3 (inclusive) above.	
5	Original Authorisation on form 1003 dated 11 August 1998.	
6	Copy Authorisation.	
7	Original Form 1010 dated 26 October 1998.	
8		
9		
10		

* falls bereits bekannt

** Der Eingang der angegebenen Unterlagen wird bestätigt. Enthält diese Spalte keine Eintragungen, so wird lediglich bestätigt, daß eine Sendung zu dem angegebenen Aktenzeichen eingegangen ist.

* if already known

** The receipt of the items indicated is confirmed. If this column does not contain any entries, it is only confirmed that an item has been received for the indicated file.

* si déjà connu

** La réception des pièces indiquées est confirmée. Faute de mention dans cette colonne, le présent accusé de réception se rapporte à une pièce quelconque envoyée sous la référence indiquée.

EPA/EPO/OEB Form 1037.2 09.95
Kopie für EPA
Copy for EPO
Copie OEB